A Multi-faceted Intervention to Improve Naloxone Co-Prescription Rates Among Primary Care Providers by Conklin, Jolane S.
Valparaiso University
ValpoScholar
Evidence-Based Practice Project Reports College of Nursing and Health Professions
4-26-2018
A Multi-faceted Intervention to Improve Naloxone
Co-Prescription Rates Among Primary Care
Providers
Jolane S. Conklin
Vaparaiso University, jolane.conklin@valpo.edu
Follow this and additional works at: https://scholar.valpo.edu/ebpr
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons,
Health and Medical Administration Commons, Nursing Commons, Primary Care Commons, Public
Health Commons, and the Substance Abuse and Addiction Commons
This Evidence-Based Project Report is brought to you for free and open access by the College of Nursing and Health Professions at ValpoScholar. It has
been accepted for inclusion in Evidence-Based Practice Project Reports by an authorized administrator of ValpoScholar. For more information, please
contact a ValpoScholar staff member at scholar@valpo.edu.
Recommended Citation
Conklin, Jolane S., "A Multi-faceted Intervention to Improve Naloxone Co-Prescription Rates Among Primary Care Providers"
(2018). Evidence-Based Practice Project Reports. 112.
https://scholar.valpo.edu/ebpr/112
   
 
 
 
  
  
 ii 
  
  
 iii 
 
 
 
 
 
 
 
Copyright © 2018 by Jolane S. Conklin  
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 iv 
DEDICATION 
This project is dedicated to family: my husband, Dan; my children, Zack and Kayla; and my 
parents, Roy and Alana.  The journey to get to this point has been arduous, and each one of 
you has made sacrifices to ensure I accomplished my goals.  Thank you for sharing the burden 
and supporting me during my educational endeavors – we made it happen! 
 
“Dripping water hollows out stone, not through force but through persistence. “ 
- Ovid 
 
  
  
 v 
ACKNOWLEDGMENTS 
I would like to acknowledge and thank Dr. Julie Koch for her unwavering support, patience, and 
wisdom throughout the course of this project.  Without her, I’m sure this project would have 
“derailed” several times.  Her commitment to her students is exemplary and does not go 
unnoticed.  
 I would also like to thank Nicole Edson, who began her nursing career with me many years ago 
and has found herself as my clinical manager.  With her support, along with that of our health 
director (Rosalind Johnston), and our fellow colleagues, this project and my educational goals 
were seen to fruition.  It truly would not have been possible without each of you.  
  
 vi 
PREFACE 
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problem, and we have to be a part of the solution.” 
-Jonathan Brown, CEO, Indian Stream Health Center  
Regarding opioid prescribing and efforts to combat the opioid epidemic 
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ABSTRACT 
A Multi-Faceted Intervention to Improve Naloxone Co-Prescription Rates  
Among Primary Care Providers 
Jolane S. Conklin, MSN, APRN, FNP-C, ADS 
It is estimated that 91 Americans die every day due to opioid overdoses, with at least half of 
those overdoses involving an opioid prescription (CDC, 2016d). To address this issue, the U.S. 
Department of Health and Human Services (USDHHS) has initiated an opioid initiative, and the 
Centers for Disease Control and Prevention (CDC) has released a clinical guideline, both of 
which include a focus on increasing use of naloxone. Despite these recommendations, 
providers often fail to co-prescribe naloxone to patients at increased risk of opioid overdose. 
The purpose of this evidence-based practice (EBP) project was to evaluate the effect of a multi-
faceted intervention (including the use of academic detailing sessions, provider reminders, and 
a clinical champion) to increase naloxone co-prescription rates within an Indian Health Services 
Tribal Health Department in the Midwestern United States.  The Iowa Model of Evidence-based 
Practice and Kotter’s Change Model were used to guide this project, which was supported by 10 
pieces of evidence obtained through a systematic search of the literature.  Retrospective chart 
audits were conducted on patients receiving opioid prescriptions of 30 days or greater during 
the 12-week intervention period and the same time period in 2016.  Descriptive statistics were 
used to compare the frequency of naloxone co-prescriptions pre-intervention (0 of 48 eligible 
patients; 0%) and post-intervention (10 of 40 eligible patients; 25%).  The 25-percentage point 
increase in co-prescribing was consistent with the supportive evidence and reflected a 
statistically significant association between the multi-faceted intervention and naloxone co-
prescription distribution (X2 = 13.538, p <.001).  Of the secondary variables of interest, only 
patient gender was associated with naloxone to a statistically significant level. Results of this 
EBP project lend support to the recommendation of use of this multifaceted approach as a 
strategy to increase naloxone co-prescription rates among primary care providers.
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CHAPTER 1 
INTRODUCTION 
Background 
 The first reference to opioids in our society has been reported to date back to Sumerian 
culture more than 6000 years ago, when it was noted that cultivation of poppy was the “plant of 
happiness” (Green, 2017).  Throughout the course of history, opioids have taken many names, 
including laudanum that was used in North America and Europe until the start of the twentieth 
century (Green, 2017).  By the year 1805, opioids began to be known by a name familiar to 
most in present day: morphine.  It was at this point that the active component of opium was 
discovered and named Morpheus, in honor of the Greek god of dreams (Green, 2017). Now, 
opioids are present in many formulations and strengths due to advances in pharmaceutical 
synthetic manufacturing (see Table 1.1 Common Opioids). 
   Opioids affect the central nervous system by binding with mu receptors, which 
regulate pain and addiction centers within the brain.  As the opioids bind to the receptors, 
physiological responses occur including pain relief, decreased respirations, mood changes, 
pupil constriction, decreased gastrointestinal tract activity, and stimulation of the receptors that 
control nausea and vomiting (Calas, Wilkin, & Oliphant, 2016).  An overdose of opioids can lead 
to significant depression of the respiratory center, thus causing cessation of spontaneous 
respiration which leads to death. 
 It has been noted that those at higher risk for prescription opioid overdose may include 
those who are taking higher doses of opioids and those who misuse (skip doses on “good” pain 
days and double up doses on “bad” pain days), inject, or take in combination with other 
substances that cause respiratory depression (e.g., benzodiazepines or alcohol) (Calas et al., 
2016; Dowell, Hagerich, & Chou, 2016; Duvivier et al., 2017).  Additionally, those who have 
other co-morbidities (e.g., advanced age, depression, lung disease, or liver disease) and those 
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who have recently had a period of abstinence from opioid use stemming from recent 
incarceration or rehabilitation may also be at higher risk (Calas et al., 2016; Dowell et al., 2016; 
Duvivier et al., 2017). Individuals who have difficulty accessing care due to remote locations, 
lack of transportation, homelessness, or without access to phone services are also considered 
high risk for opioid overdose (Calas et al., 2016; Dowell et al., 2016; Duvivier et al., 2017). 
 Naloxone, a medication developed in 1971 as a prescription formulation, and until 
recently used primarily in hospital settings, is an opioid antagonist that works by binding with the 
mu receptors in the brain (Calas et al., 2016; Jacobs, 2016).  In doing such, opioids are 
displaced from the mu receptors, thus reversing the effects of central nervous system 
depression, effectively reversing the physiological symptoms of an opioid overdose; but, 
naloxone has a half-life of only approximately 30 to 90 minutes, so as the effects wear off, 
opioids that remain circulating in the blood will again bind to the mu receptors (Calas et al., 
2016).  Although naloxone’s short half-life only buys an opioid overdose victim time for further 
intervention, it does allow a window of opportunity to access higher level care services. Unique 
to naloxone, due to its mechanism of action, are no adverse effects to those individuals who 
would happen to receive a dose in the absence of a true opioid overdose situation (Calas et al., 
2016; Duvivier et al., 2017).  This potentially life-saving medication has been named as a 
component in various opioid initiatives, with a push to expand access of naloxone to lay-users 
who may be at risk for opioid overdose themselves or have known family and friends who may 
be at risk for opioid overdose (Calas et al., 2016; Centers for Disease Control and Prevention 
[CDC], 2016a; Duvivier et al., 2017; Mueller, Walley, Calcaterra, Glanz, & Binswanger, 2015). 
Statement of the Problem 
Data from the Literature Supporting Need for the Project 
As unintended overdoses from opioid drugs continue to climb in the United States (U.S.), 
community members, health care professionals, and government agencies are searching 
intensely for solutions to combat the escalating epidemic.  Those who suffer from addiction and 
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those that have the potential for overdose due to legally prescribed and obtained medications, 
as well as their families, are demanding that something be done.   
The CDC (2016c) has reported that opioids were involved in 28,647 deaths (61% of all 
drug overdose deaths) in the U.S. in 2014 and that opioid overdoses have quadrupled since 
1999.  During this same timeframe, the number of prescriptions written for opioid medications 
also quadrupled, despite no increased reports of the level of pain in Americans (CDC, 2016c).  
Additionally, it is estimated that 91 people in the U.S. die every day due to opioid overdoses, 
with at least half of those overdoses involving an opioid prescription (CDC, 2016d). 
Furthermore, 1,000 people are treated every day in emergency departments across the country 
for conditions related to not using opioid prescriptions as directed (CDC, 2016c). 
The State of Michigan saw a statistically significant increase in opioid death rates 
(13.3%) between 2014 and 2015 and had one of the highest overdose death rates in the nation: 
20.4 per 100,000 population (CDC, 2016b).  In 2015, drug overdose was the leading cause of 
injury death in Michigan, outpacing motor vehicle accidents, firearm discharge, and suicide 
(CDC, 2016d).  Furthermore, not only has geographic focus been a concern, but so has the 
status of populations that historically have been known to be at higher risk: Native Americans.  
Drug-related deaths among Native American Indians and Alaskan Natives increased from 5 per 
100,000 population between 1989-1991 to 22.7 per 100,000 population between 2007 and 2009 
(Indian Health Services [IHS], 2015). The rate of drug-related deaths among Native Americans 
was almost twice that of all races in the same time frame (IHS, 2015), and in 2015, unintentional 
poisoning (drug overdose), was the leading cause of injury death among Native Americans in 
Michigan (CDC, 2016d). 
Prescription opioids, while initially utilized for legitimate purposes, have been shown to 
lead to higher rates of opioid usage.  A recent study found that even one prescription for opioids 
can be a trigger for abuse (Shah, Hayes, & Martin, 2017).  Additionally, the risk of long term 
opioid use increases sharply when patients are given (a) a long-acting opioid, (b) a 10- to 30-
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day supply, (c) more than 700 morphine milligrams cumulative dose, or (d) if they return for a 
second prescription or refill (Shah et al., 2017). 
Recognizing that prescription opioid use has the potential for overdose and can be 
viewed as a gateway to illicit drug use, both of which have reached epidemic levels, in March 
2015, the U.S. Department of Health and Human Services (USDHHS) released their opioid 
initiative, which highlights three priority areas of focus to address opioid drug and heroin 
overdose and death: (a) provide training and education resources, (b) increase use of naloxone, 
and (c) expand the use of medication-assisted treatment (USDHHS, 2016).  Following that 
national initiative, in March 2016, the CDC released a clinical guideline for prescribing opioids 
for chronic pain to combat the present epidemic (CDC, 2016a).  The guideline contains 12 
recommendations regarding safe opioid prescribing.  Among these, a focus on assessing risk 
and addressing harms of opioid use exists, namely offering co-prescriptions of naloxone when 
prescribing opioids to patients at increased risk of overdose (CDC, 2016a). 
Data from the Clinical Agency Supporting Need for the Project 
Located in Southwest Michigan, the clinical agency was part of a rural tribal health 
department located on reservation land and partially funded by Indian Health Services (IHS).  
Facilities also included two other satellite locations, one in an urban area and one located inside 
a nearby occupational setting. These clinics provide primary care services, dental services, 
social and behavioral health services, nutrition services, and community health services to all 
federally recognized tribal members, their family members, and the employees of the 
organization.  As much as possible, all three clinics attempt to provide comparable services and 
abide by the same policies and procedures. 
 A recently completed health needs survey of area tribal members confirmed concerns 
previously identified by health care providers in the clinic:11.9% of tribal members surveyed 
reported using a prescription drug for experience (i.e., the feeling it caused or to get high), well 
above the 4.7% average lifetime prevalence of all races (Great Lakes Inter-Tribal Epidemiology 
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Center, 2016).  Additionally, 3.97% of those surveyed reported misuse of prescription drugs 
within the past 30 days (Great Lakes Inter-Tribal Epidemiology Center, 2016).  Furthermore, in 
reviewing adverse childhood experiences (ACEs), which have been shown to  correlate with 
increased risk of opioid misuse, 24.23% of those surveyed reported living with a problem drinker 
or alcoholic before the participant turned 18, and 11.03% indicated the same circumstances 
regarding living with someone who abused illegal street drugs or prescription drugs (Great 
Lakes Inter-Tribal Epidemiology Center, 2016). 
 Both the current rates of misuse of prescription medications, as well as the reported 
level of ACEs, confirmed the significance of the problem to the tribal health department staff, 
specifically the prescribing providers. As a result, the prescribing providers felt compelled to 
review previous polices regarding controlled substance prescribing. 
 The clinical agency did have an existing policy that was developed prior to the 
employment of the current providers and clinical manager, but the policy did not address several 
present-day issues (i.e., recently published guidelines for safe prescribing, and inclusion of 
prescription monitoring database programs).  Discussions at group meetings between the 
Doctor of Nursing Practice (DNP) student facilitator, the clinical manager, the medical director 
(an internal medicine physician), two physician assistants (PAs), and one staff physician echoed 
the same themes: (a) the current practice policy was outdated and needed to be reviewed, (b) 
safe opioid prescribing practices needed to be addressed systematically, and  (c) providers did 
not feel well versed in current guidelines and were uncertain of how to adequately prevent 
opioid overdose. 
 During this same timeframe, the local tribal government that provided clinic oversight, 
expressed their concern in taking a proactive approach to opioid overdose prevention across all 
tribal lands and properties; the organization implemented a naloxone distribution policy for those 
at risk for overdose. The combination of provider discussions regarding outdated controlled 
substance policies, tribal governmental policy changes, and national opioid prescribing guideline 
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updates prompted Clinic X provider discussion regarding (a) the identification of those at risk for 
opioid overdose and (b) the ability and appropriateness of prescribing naloxone for overdose 
death prevention.  The providers identified barriers to prescribing naloxone for current clinic 
patients: proper identification of appropriate candidates, unfamiliarity with current guideline 
recommendations of co-naloxone prescribing, patients not self-identifying as an overdose risk, 
and general lack of knowledge regarding the technicalities of writing a naloxone prescription 
(Clinic X Manager, personal communication, March 1, 2017).  One provider anecdotally 
reported having written a naloxone prescription only once, at the request of the family, while the 
other providers reported having never written a naloxone prescription (Providers of Clinic X, 
personal communication, March 1, 2017).  Despite the lone provider’s indication of prescribing 
naloxone, evaluation of eligible patients between September 25, 2016 through December 15, 
2016, demonstrated 48 patients receiving chronic opioids prescriptions of 30 days or greater; 
none of which received a naloxone co-prescription. 
Purpose of the Evidence-Based Practice Project 
Compelling Clinical Question 
 An agency and community-wide push to become proactive in opioid overdose prevention 
demonstrate the need for a time-efficient, evidence-based practice (EBP) project which would 
incorporate a thorough review of current practice standards and guidelines as well as aid in 
identifying barriers and implementing strategies that would help improve naloxone co-
prescription rates among clinic patients who received chronic opioid prescriptions.  Thus, the 
development of the compelling clinical inquiry arose: What are the best strategies for improving 
provider rates of naloxone co-prescriptions to those receiving chronic opioid medications in a 
primary care setting? 
PICOT Question 
 Melnyk and Fineout-Overhold (2011) have noted that once there is awareness of a 
compelling clinical inquiry, then a clinical question can be developed.  To guide the development 
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of this project and facilitate the procurement of the best available evidence, the PICOT (patient 
population, intervention of interest, comparison intervention or status, outcome and timeframe) 
format was used.  Utilizing this PICOT format led to the development of the question for this 
project: (P) Among primary care providers in a tribal health clinic, (I) does the introduction of an 
evidence- based multi-faceted intervention (C) versus the current practice of no tool, (O) 
improve the co-prescription rates of naloxone to chronic opioid patients (T) within a 12- week 
period? 
Significance of the EBP Project 
The goal of this EBP project was to improve naloxone co-prescription rates among clinic 
providers for the purpose of taking a proactive approach to opioid overdose death prevention.  
With the release of CDC guidelines in early 2016, providers were given guidance on safe 
prescribing practices and recommendations which, in the midst of the opioid epidemic plaguing 
not only the United States, but the world, were desperately needed (Dowell et al., 2016).  
However, due to time gaps from publication to disseminating and implementing these guidelines 
fully into today’s complicated primary care structure, the benchmark for the level of guideline 
adherence had not been established. 
As the opioid overdose crisis continues to morph, primary care clinicians are poised in a 
pivotal juncture to both limit the opioids being prescribed and aid in the access to interventions 
in the event of accidental or intentional overdoses.  There is significant literature that indicates 
primary care providers feel neither confident nor empowered to approach patients with the 
pretense to simply discuss potential adverse outcomes of opioid substances, much less feel 
comfortable to discuss naloxone co-prescriptions and actually dispense them (Binswanger et 
al., 2015; Kerensky & Walley, 2017; Mueller et al., 2015; Wilson, Rodriguez, Carrington, & 
Fagan, 2017).  Although the opioid epidemic is far-reaching, and the answer does not lie with a 
single intervention, providers must exercise caution in regard to opioid prescribing and their 
duty, both ethically and legally, to prevent any unintended consequences.  It is with that 
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intention, that this EBP project was developed…with the altruistic goal of preventing the loss of 
life by focusing on a single aspect of the battle: improvement of naloxone co-prescription rates 
in the primary care setting. 
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Table 1.1 
Commonly Prescribed Opioids 
Generic Brand Name Half-life (hours) 
Buprenorphine Buprenex, Butrans 24-60 
Codeine Capital/Codeine, Tylenol with 
Codeine #3, Tylenol with 
Codeine #4  
4 
Fentanyl Abstral, Actiq, Duragesic, 
Fentora, Lazanda,Lonsys, 
Onsolis, Subsys 
2-4 
Hydrocodone Lorcet, Lortab, Maxidone, 
Norco, Reprexain, Stagesic, 
Verdrocet, Vicodin, 
Vicoprofen, Xodol, Xylon, 
Zydonelbudone 
3-5 
Hydromorphone Dilaudid 2-3 
Meperidine Demerol, Meperitab 2.5-4 
Methadone Dolophine, Methadose 8-59 
Morphine Astramorph, Duraporph, 
Infumorph, MSContin 
2-4 
Oxycodone Endocet, Endodan, Magnacet, 
Percocet, Percodan, Primlev, 
Roxicet, Roxicodone   
2-4 
Oxymorphone Opana 7-9 
Note: Adapted from Epocrates Plus, (2017). 
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CHAPTER 2 
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE 
Theoretical Framework 
Melnyk and Fineout-Overholt (2015) defined evidence-based practice (EBP) as “a 
paradigm and lifelong problem-solving approach to clinical decision making that involves the 
conscientious use of the best available evidence with one’s own clinical expertise and patient 
values and preferences to improve outcomes for individuals, groups, communities and systems” 
(p. 604). Implementing EBP into clinical practice can be challenging due any number of barriers 
hindering the process.  Therefore, utilizing a model to systematically guide the implementation 
of EBP can be beneficial (Melnyk & Fineout-Overholt, 2015).  
To facilitate the translation of evidence into clinical practice within this DNP project, the 
Iowa Model of Evidence-Based practice was incorporated.  The DNP student facilitator used the 
Iowa Model to integrate current high-quality evidence into clinical practice, with consideration of 
the targeted population’s clinical status and circumstances, their preferences and expertise, 
available resources, and current beliefs.  Aware of the importance for a systematic approach to 
aid in successful implementation, the DNP student facilitator also incorporated Kotter’s Model of 
Change as the theoretical framework to guide the change processes that were intended to 
increase naloxone co-prescription rates among primary care providers in the project facility.   
Overview of Theoretical Framework 
 John Kotter’s Model of Change, although not widely utilized in nursing until more recent 
years, has provided a model to effectively introduce change into an organizational environment 
(Schmidt & Brown, 2015).  Kotter proposed an 8-step change model which has been described 
as a “top down” transformation process, an effective strategy to implement changes in phases 
while encompassing strategies to overcome barriers and challenges (Schmidt & Brown, 2015).  
This model was determined to be well suited to this DNP project due to its simplicity and focus 
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on changing group behavior. The eight steps include (a) establishing a sense of urgency, (b) 
creating a powerful guiding coalition, (c) developing a vision, (d) communicating the vision, (e) 
empowering others to act on the vision, (f) planning for and create short-term wins, and (g) 
institutionalizing new approaches (Borkowski, 2016).  
Application of Theoretical Framework to EBP Project 
 The first step of Kotter’s 8-step process involves creating a sense of urgency 
(Borkowski, 2016).  Within this DNP project, a sense of urgency was established as tribal 
leaders recognized a growing problem with opioid overdoses. A recent survey among the tribal 
members had highlighted that prescription misuse was occurring at much higher rates than 
presumed (Great Lakes Inter-Tribal Epidemiology Center, 2016).  It became evident that it was 
only a matter of time before an unintended overdose occurred within the clinic population.  Clinic 
X’s health care providers were invited to attend symposiums with local, regional, and national 
leaders that addressed the significance of rising rates of overdoses within the community and 
further supported the need for an intervention to urgently address the problem. Although a 
policy that was developed solely by the clinical manager had been developed, the providers had 
voiced concerns that, to prevent unintentional harm and ensure they were incorporating current 
safety and risk mitigation strategies, they needed to have access to the most current opioid 
prescribing guidelines.   
 The second step of Kotter’s process involves creating a coalition (Schmidt & Brown, 
2015).  This task was easily completed as various stakeholders including governmental leaders, 
tribal police, health department administration, and prescribing providers all recognized the 
significance of the problem.  A controlled substance (CS) task force, comprised of the clinical 
manager and all five providers, was formed to review, and address any gaps within current 
practice standards and policies.   
 The third step within Kotter’s process involves developing a vision (Schmidt & Brown, 
2015).  The singular vision of the CS task force was to promote the safe prescribing of high-risk 
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substances in order to prevent unintentional consequences.  However, it was understood that to 
accomplish this greater vision, the task had to be undertaken in a systematic fashion: reviewing 
current practices, identifying gaps and variances from recent practice change 
recommendations, and implementing practice changes to address identified issues.   
 These previous steps led to the fourth step, communicating the vision (Schmidt & Brown, 
2015).  Although key stakeholders all recognized the sense of urgency regarding this matter, 
several felt that available information was not only confusing, but was also, at times, conflicting.  
The clinical manager and providers were supportive in allowing the DNP student facilitator to 
take the lead on this task force, finding relevant information and communicating to appropriate 
stakeholders, both within the health department and throughout the tribal government of the 
DNP project facility.  Regular communication throughout the gap analysis, evidence search, and 
policy development was essential to maintaining the vision. 
 Establishing urgency, creating a coalition, developing a vision, and communicating that 
vision, while being the bulk of the process, do not result in practice and organizational changes.  
The fifth step in the 8-step process is actually the beginning of intended changes (Schmidt & 
Brown, 2015).  During the fifth stage, empowering others to act on the vision becomes 
imperative for organizational change (Borkowski, 2016). The ability to remove barriers to 
proceed with change, as well as use creative thinking and problem solving, becomes imminent 
to the success of EBP implementation.  Within this DNP project, utilization of the first four steps 
provided a foundation which successfully empowered others and ultimately garnered Clinic X’s 
administrative support to pursue practice changes.  Key stakeholders’ attendance to the 
symposiums prompted non-clinical administrative personnel as well as clinical personnel to 
recognize the magnitude and urgency of addressing this problem.  Perceived barriers 
addressed by staff included technical and administrative barriers related to the current EHR, 
lack of understanding as to how and when the current policies were developed, fear of creating 
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a sense of mistrust or insulting current patient populations with potential misplaced stigmas, and 
a general lack of knowledge regarding current recommended guidelines. 
 Kotter’s sixth step involves planning for and creating short-term wins (Borkowski, 2016).  
This was achieved through regular reporting by the DNP student facilitator of status and 
naloxone distribution updates throughout the implementation stage.  Providers and the clinical 
manager expressed a sense of empowerment and satisfaction towards combating the opioid 
epidemic in the project facility.  The sense of accomplishment of contributing to the solution 
(overdose prevention) rather than contributing to the problem (opioid misuse and overdose) was 
crucial in maintaining the enthusiasm that would anchor practice changes. 
 The seventh step in Kotter’s change model, consolidating improvements and producing 
more change (Schmidt & Brown, 2015), is the last step prior to institutionalizing changes.  The 
seventh step, while sequential in the process, occurred concurrently with step six during this 
DNP project.  Small wins in the sixth step fueled motivation to continue to examine other 
process improvements that could be implemented to support the vision created in step two of 
the change process. 
 The eighth and final step in Kotter’s change model involves institutionalizing new 
approaches (Borkowski, 2016).  This step is crucial in the process. Without it, practice changes 
may not be anchored, providers may become unmotivated or lackadaisical; therefore, practice 
improvements have the potential to return to previous status.  To mitigate this potential pitfall, 
communication and updates were provided at monthly provider meetings and shared 
periodically at monthly all-staff meetings.  Staff who may not have been directly involved in the 
task force, due to lack of prescribing privileges, were also included to lessen stigma surrounding 
overdose education and naloxone distribution (OEND) and to provide prescribing providers 
support in DNP project interventions.  To further anchor change, plans were made for the DNP 
student facilitator to continue to act as the clinical champion after the project intervention period 
ended. The clinical manager will also remain involved and will be responsible for the 
NALOXONE CO-PRESCRIBING  14 
 
  
procurement of additional naloxone stock. Updates and necessary modifications will continue to 
be discussed at monthly provider meetings.   
Strengths and Limitations of Theoretical Framework for EBP Project 
 While Kotter’s model has identified creating a sense of urgency as the impetus for 
change, individuals have often been motivated by an emotional trigger to act.  Although the 
Kotter model has been identified as a team-based model, individuals may be at different levels 
of priority in terms of urgency, thus creating an imbalance of motivation.  However, if individuals 
have experienced a situation which created an emotional investment in the necessitated 
change, that experience could spur them to action at a faster pace (Schmidt & Brown, 2015).  
Within Clinic X, although the DNP student project facilitator was the first to broach the topic of 
overdose prevention with the other providers, they quickly became emotionally motivated after 
attending the aforementioned symposia and grasping the breadth of the problem at hand. 
 Also, as Kotter’s model has been identified as a team-based model, it also became 
evident that it was initially developed to be delivered from a management position (Schmidt & 
Brown, 2015).  Yet, having the right mix of team members has been imperative to success, as a 
team that is composed of a higher ratio of management staff might foster a sense of 
intimidation.  It has also been deemed important to maintain a balanced and well-round coalition 
of stakeholders, since a variety of experiences and opinions can provide an environment to 
create and sustain practice changes (Schmidt & Brown, 2015). 
 A significant limitation of applying Kotter’s change model to this DNP project was the 
time constraints in which to fully deploy and anchor change within the organization.  Since the 
DNP project was conducted in a relatively brief window of time, it was difficult to spend an 
ample amount of time on each sequential step.  The limited time for implementation had the 
potential, for those who may have been faced with a heavier workload than usual to implement 
project driven practice changes, to develop a sense of burden, rather than empowerment.  
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Therefore, it became essential to pay close attention to step six, creating short term wins (to 
acknowledge their successes) to continue to propel change. 
Evidence-based Practice Model 
Melnyk and Fineout-Overholt (2015) stated that “It is not enough to have knowledge of 
the best evidence to guide clinical practice; that knowledge must be translated into clinical 
practice to improve patient care and outcomes.” (p. 202).  While many health care providers 
have been highly motivated to integrate EBP into their clinical routines, the processes may be 
fraught with organizational obstacles.  Incorporating a systematic process model to guide the 
implementation of EBP can be beneficial to anticipate and overcome these barriers. 
Overview of EBP Model 
 The Iowa Model of Evidence-Based Practice to Promote Quality Care has been used 
successfully within hospitals and other organizations to guide implementation of EBP (Melnyk & 
Fineout-Overholt, 2015).  This process model was originally developed in 1994 by M. Titler and 
was based on her experiences (Melnyk & Fineout-Overholt, 2015).  Based on feedback from its 
users, the model has undergone revisions, indicating that as our knowledge fund of 
implementing EBP has expanded, thus too must the model change to incorporate our improved 
utilization (Titler et al., 2001).  The revised model included new terminology and feedback loops, 
addressed changes in the health care market, and supported the use of other types of evidence 
when research findings were unavailable to guide practice (Titler et al., 2001). 
    The first step of the Iowa Model is to identify a problem focus or knowledge focus 
trigger where an EBP change may be warranted (Melnyk & Fineout-Overholt, 2015).  The next 
step in the process is to determine if the problem is identified as a priority for the organization.  
This an important step in the process because identifying a problem as a priority to the 
organization will help garner support to complete the EBP project (Melnyk & Fineout-Overholt, 
2015).  The following step includes assembling a team of stakeholders which will help to 
develop, implement, and evaluate practice change (Melnyk & Fineout-Overholt, 2015).  Once 
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the team is assembled, they will need to evaluate and synthesize available literature.  At this 
junction, a decision point is encountered.  If it is determined that there is not enough literature 
available, the team may decide to conduct the needed research themselves or base practice on 
other types of research such as case reports, expert opinions, scientific principles, or theories.  
Otherwise, if it is determined that there is enough available literature to proceed, the team will 
conduct a pilot change within the practice setting.  At the conclusion of the pilot, the team will 
evaluate if the change was appropriate to be adopted into practice or if additional changes need 
to be made.  If it is appropriate, the practice change will be implemented, and the results 
disseminated (Melnyk & Fineout-Overholt, 2015). 
Application of EBP Model to EBP Project 
 The Iowa Model was chosen for this project because it provided an organized team-
based approach to implementing evidence-based practice changes.  Initially, a problem-focused 
trigger was identified: co-prescribing of naloxone was identified as a risk mitigation strategy in 
recent guideline updates but was not actively being done by prescribing providers within the 
DNP project facility (CDC, 2016a).  It was determined that, due to recent heightened awareness 
of potential overdose risks within the community, this problem was indeed a priority.  As 
indicated by the step-wise approach of the Iowa Model, a team was assembled to develop, 
implement, and evaluate an EBP change.  The team was comprised of several multi-disciplinary 
members, including the clinical manager, the DNP student facilitator, and the prescribing 
providers (two PAs and two physicians).  The PICOT question was formed, and a thorough 
literature search was conducted. 
 After the literature search was conducted, relevant findings were appraised and 
synthesized to identify the current best practice to improve provider co-prescriptions rates of 
naloxone.  The pilot intervention change in practice was identified and a detailed plan of the 
intervention and evaluation strategies was submitted to Valparaiso University’s institutional 
review board (IRB) for approval.  As the project facility did not have a formal IRB, team 
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members reviewed the proposed intervention for any concerns during a regularly scheduled 
meeting.  After all approvals were obtained, the project intervention was implemented into a pilot 
practice change.  Finally, the project intervention was reviewed at the completion of the pilot 
period and results were analyzed, reviewed, discussed, and anchored into a practice change.  
Ongoing monitoring and analysis of the current EBP literature and intervention continue to 
ensure the intervention remains relevant and appropriate. 
Strengths and Limitations of EBP Model for EBP Project 
 The Iowa Model possessed several strengths to guide this project.  First, although 
developed by members of the nursing profession, it provided a simplified approach that has 
been easily understood by a variety of members within a multi-disciplinary team (Melnyk & 
Fineout-Overholt, 2015).  Second, the Iowa Model provided a systematic, step-wise approach 
with key decision points on whether to proceed or return to previous steps, thus ensuring best 
methods were utilized throughout the process.  Finally, although this EBP project was led by the 
DNP student facilitator, the Iowa Model supported a process which incorporated team members 
to be actively involved, which improved stakeholders’ investment within the intervention. 
 A limitation of utilizing the Iowa Model to guide this EBP project would be the time 
constraints of the continued process for ongoing analysis and implementation.  As this project 
intervention was conducted on a timeline directed by the educational partnership, there was no 
opportunity to continue with appropriate revisions to the intervention or further analysis of those 
revisions.  Furthermore, the model did not provide guidance to the team through the data 
collection and analysis component, which limits its applicability for disseminating project findings 
to other practitioners who may want to replicate the project themselves.  Specific input regarding 
analysis and data collection could be beneficial for future revisions of the model and applicability 
to EBP projects. 
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Literature Search 
Sources Examined for Relevant Evidence 
An extensive literature search was conducted using multiple database sources including 
CINAHL, PsychINFO, Joanna Briggs Institute, Cochrane Library, MEDLINE (via EBSCO), 
ProQuest, and PsychArticles.  Due to the rapidly changing literature available regarding this 
topic, an extensive hand search was also completed in an effort to obtain all current relevant 
research available.  A variety of keywords and medical subject headings (MeSH) were trialed 
during this search.  The final set of terms utilized during the literature search included “naloxone 
AND prescri* AND opioid* OR opiate* AND primary OR pharm*.”  A complete list of the search 
terms and number results found in each database can be found in Table 2.1.   
Inclusion criteria for the literature search encompassed a publication date between 2015 
and 2017, English language, scholarly or academic journals, and peer-reviewed journals.  The 
narrow, recent publication window was selected since the CDC opioid prescribing guideline 
(CDC, 2016a), which had been adopted by most, if not all major organizations was introduced in 
March 2016, thus making many previous studies obsolete or clinically irrelevant.  Since the 
CDC’s guideline was particularly relevant to this project, the literature search focused on 
evidence that was published near or after the time of guideline release.   
The literature search yielded 259 articles, of which 65 were duplicates.  A review of titles 
and abstracts resulted in 36 articles being deemed worthy of further review based on inclusion 
criteria.  After reviewing the 36 articles, the DNP student facilitator selected a total of eight 
articles based on level of evidence and quality of evidence.  Additional hand searching resulted 
in two other articles being included within the final evidence table (Table 2.2). 
Articles were included if they pertained to prescribing providers, were in primary care or 
outpatient clinic settings and had interventions related to naloxone co-prescribing rates.  
Exclusion criteria included evidence that specifically pertained to (a) hospital settings, (b) 
community-based distribution programs, (c) emergency medical services naloxone 
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administration, (d) police naloxone administration, and (e) oncology diagnoses.  Evidence was 
also excluded if the intervention focused only on patient populations, rather than health care 
providers, or if pregnancy was involved.  Articles that included use of pharmacists or pharmacy-
based distribution were evaluated individually for relevance and considered for inclusion if they 
utilized interventions that could either be incorporated into a primary care setting or if they 
utilized interventions to improve naloxone co-prescribing rates. 
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Table 2.1 
LITERATURE SEARCH RESULTS 
DATABASE SEARCH TERMS LIMITERS ARTICLES 
YIELDED 
DUPLICATES ABSTRACTS 
RIVEWED 
ARTICLES 
USED 
CINAHL naloxone AND prescri* AND 
opioid* OR opiate* AND 
primary OR pharm* 
2015-2017, 
English, Peer-
Reviewed 
30 0 11 2 
PsychINFO naloxone AND prescri* AND 
opioid* OR opiate* AND 
primary OR pharm* 
2015-2017, 
English, Peer-
Reviewed 
43 9 11 0 
Joanna Briggs 
Institute 
naloxone  2015-2017 4 0 0 0 
Cochrane naloxone AND prescri* AND 
opioid* OR opiate* AND 
primary OR pharm* 
2015-2017, 
Cochrane 
Reviews 
5 0 0 0 
MEDLINE (via 
EBSCO) 
naloxone AND prescri* AND 
opioid* OR opiate* AND 
primary OR pharm* 
2015-2017, 
English, Peer-
Reviewed 
102 47 12 6 
ProQuest naloxone AND prescri* AND 
opioid* OR opiate* AND 
primary OR pharm* 
“naloxone” in abstract 
2015-2017, 
English, Peer-
Reviewed 
39 9 2 0 
PsychArticles naloxone AND prescri* AND 
opioid* OR opiate* AND 
primary OR pharm* 
2015-2017, 
English, Peer-
Reviewed 
0 0 0 0 
Handsearching naloxone 2015-2017, 
English 
0 0 0 2 
TOTAL N/A N/A 259 65 36 10 
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Levels of Evidence  
A total of 10 sources of evidence were deemed worthy for inclusion into the supportive 
literature for this EBP: one randomized controlled trial (RCT), two quasi-experimental, two 
descriptive studies, three program evaluations, one quality improvement project, and one 
consensus statement.  The ten sources were evaluated using the Johns Hopkins Research 
Evidence Based Practice Research Appraisal Tool, and an evidence level was assigned, 
ranging from level I to level V, with level I being the highest level of evidence and level V, being 
the lowest level respectively (Dearholt & Dang, 2014).  The sources in the literature review were 
further appraised for quality utilizing the Johns Hopkins Nursing Evidence-Based Practice 
Research Evidence Appraisal Tool or the Non-Research Evidence Appraisal Tool (Dearholt & 
Dang, 2014). 
Using the Johns Hopkins Research Evidence Based Practice Appraisal Tool, research 
studies receive a level of I, II or III, depending on their design.  RCTs or experimental studies 
receive the highest level of I, while quasi-experimental studies are considered a level II, and 
non-experimental or qualitative studies are considered a level III (Dearholt & Dang, 2014).  
Likewise, summaries of multiple research studies are stratified in a similar manner.  Systematic 
reviews, meta-analysis and meta-synthesis studies are appraised with consideration of the 
studies included within the reviews.  For example, if all the studies contained within the review 
are RCTs, a level I would be given.  If studies are a combination of RCTs and quasi-
experimental or quasi-experimental only, a level II would be appropriate.  A level III rating is 
given if the studies included with the review are a combination of RCTs, quasi-experimental and 
non-experimental studies, or non-experimental studies only.  If any of the studies contained 
within the systematic review are qualitative, then a level III is required (Dearholt & Dang, 2014). 
The Johns Hopkins Non-Research Evidence Appraisal Tool rates other evidence in 
much the same fashion.  Clinical practice guidelines, consensus or position statements are a 
level IV, while literature reviews and expert opinions are given a level V ranking.  Additionally, 
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organizational experiences are appraised as a level V if they are quality improvement initiatives, 
financial evaluations, or program evaluations.  Case reports, community standards, clinician 
experience and consumer preference are also considered a level V (Dearholt & Dang, 2014). 
The DNP student facilitator ranked the literature that was included for relevant evidence 
by the standards explained above.  The one RCT (Behar, Rowe, Santos, & Coffin, 2017) was 
ranked as level I evidence.  Two pieces of evidence were considered level II: a retrospective, 
repeated measures cohort study (Bounthavong et al., 2017) and a quasi-experimental study 
(Coffin et al., 2016).  Two pieces of evidence, both descriptive studies were considered a level 
III (Behar et al., 2016; Winograd, Davis, Niculete, Oliva, & Martielli, 2017).  The bulk of the 
evidence collected was considered non-research and was leveled as such.  One consensus 
statement was rated as a level IV (Alexander, Frattaroli, & Gielen, 2015), while the remainder of 
the evidence pieces were ranked as level V: three program evaluations (Devries, Rafie, & 
Polston, 2017; Oliva et al., 2017; Wilson et al., 2017), and one exploratory pilot project 
(Delaney, Huff, Mini, Thomas, & Tremaglio, 2016),. 
Appraisal of Relevant Evidence   
The ten pieces of evidence in the literature reviewed were also appraised for quality, 
using the Johns Hopkins Research and Non-Research Evidence Appraisal Tools.  These tools 
incorporate the use of quality ratings based on quality appraisal; there are three different quality 
levels: (A) high quality, (B) good quality, and (C) low quality or major flaws (Dearholt & Dang, 
2014). 
In relation to pieces of evidence that are appraised with the Johns Hopkins Research 
Evidence Appraisal Tool, a grade A, high quality, rating is reached if the study is consistent, with 
generalizable results, sufficient sample size for the study design, adequate control, definitive 
conclusions, and if there are consistent recommendations based on comprehensive literature 
review that includes thorough reference to scientific evidence (Dearholt & Dang, 2014).  A grade 
B, good quality, rating is achieved if there are reasonably consistent results, sufficient sample 
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size for the study design, some control and fairly definitive conclusions, and reasonably 
consistent recommendations based on fairly comprehensive literature review that includes some 
reference to scientific evidence (Dearholt & Dang, 2014).  A low quality, grade C, is given if 
there is little evidence with inconsistent results, insufficient sample size for the study design, or if 
conclusions cannot be drawn (Dearholt & Dang, 2014). 
The Johns Hopkins Non-Research Evidence Appraisal Tools are evaluated more 
specifically to the type of evidence being evaluated but are still given the same quality levels: 
(A) high quality (B) good quality and (C) low quality or major flaws (Dearholt & Dang, 2014).  
Level IV evidence (i.e., clinical practice guidelines, consensus, or position statements) are 
evaluated in regards to (a) material officially sponsored by a professional, public, or private 
organization or government agency; (b) documentation of a systematic literature search 
strategy, (c) consistent results with sufficient numbers of well-designed studies, (d) criteria-
based evaluation of overall scientific strength and quality of included studies and definitive 
conclusions, and (e) national expertise that is clearly evident and has been developed or 
revised within the past five years.  If the previous criteria are met, a high quality (A) rating would 
be given (Dearholt & Dang, 2014).  A good quality (B) rating would be considered if the material 
meets the criteria above, but only indicates a reasonably thorough and appropriate systematic 
literature search strategy, reasonably consistent results, and there is evaluation of strengths and 
imitations of included studies with fairly definitive results (Dearholt & Dang, 2014).  A low quality 
or major flaws rating (C) would be given if the literature (a) was not sponsored by an official 
organization or agency, (b) included an undefined, poorly defined or limited literature search 
strategy, (c) had no evaluation of strengths and limitations of included studies, (d) presented 
insufficient evidence with inconsistent results, (e) lacked the ability to derive conclusions, or (f) 
had not been revised within the last five years (Dearholt & Dang, 2014). 
Level V evidence for organization experience is awarded a high quality (A) rating if there 
are clear aims and objectives, consistent results across multiple settings, formal quality 
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improvement or financial evaluation methods used, definitive conclusions, and consistent 
recommendations with a thorough reference to scientific evidence (Dearholt & Dang, 2014).  A 
good quality (B) rating meets the majority of the high quality (A) criteria but has consistent 
results in only a single setting and/or reasonably consistent recommendations with some 
reference to scientific evidence (Dearholt & Dang, 2014).  A low quality of major flaw (C) rating 
is appropriate when there is unclear of missing aims or objectives, inconsistent results, or poorly 
defined quality improvement/financial analysis method, or when recommendations cannot be 
made (Dearholt & Dang, 2014). 
When Level V evidence (i.e., literature reviews, expert opinions, community standards, 
clinician experience, and consumer preference) is evaluated, a high quality (A) rating is 
appropriate if the expert provides clearly evident expertise, draws definitive conclusions, 
provides scientific rationale, and is recognized as a thought leader in the field.  A good quality 
(B) rating is given if the author’s expertise appears to be credible and he or she draws fairly 
definitive conclusions and provides logical argument for opinions.  Finally, a low-quality, major 
flaws (C) rating is indicated if the author’s expertise is not discernable or is dubious or if 
conclusions cannot be drawn (Dearholt & Dang, 2014).  
Level I Evidence 
Behar et al. (2017) conducted a good quality (B rating) study that included an academic 
detailing (AD) intervention to 40 randomly selected opioid prescribing primary care providers (n 
= 40, N = 143) in the San Francisco area over a 3-month time frame in 2015.  Written materials, 
including a patient brochure and a provider educational booklet, were developed under the 
guidance of appropriate experts within the field.  The provider educational booklet included 
information on state and national opioid overdose statistics, patient-level overdose risk facts, 
rationale for furnishing a naloxone co-prescription to patients receiving long term opioids, 
naloxone pharmacology, effectiveness and cost effectiveness of naloxone, and indicators for 
prescribing, as well as guidance on how to educate patients on naloxone and opioid overdoses.  
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Information regarding state laws and examples of how to prescribe depending on formulation 
type were also included.  A detailing visit reviewed the developed materials and a 1-page 
instruction sheet for registering for the prescription drug monitoring program, a 1-page opioid 
morphine milli-equivalent (MME) calculator, and two articles addressing the effectiveness and 
cost effectiveness of naloxone.  The academic detail included a 5- to 60-minute (m = 28 
minutes) discussion regarding the elements of the handouts.  Discussions were not fixed, but 
instead were tailored to meet the needs and interests of the individual providers.  Providers 
were contacted two to three months after the detailing and again at six to nine months after the 
intervention to establish if they had, indeed, prescribed naloxone.   
Medi-Cal data for each provider was obtained, including the number of naloxone 
prescriptions that had been filled in the four months before and after the intervention.  Among 
the detailed providers, the number of providers that issued naloxone prescriptions increased 
from 0 to 3 providers, while the number of naloxone prescriptions filled increased from 0 to 10 
prescriptions filled.  Behar et al. (2017) reported a statistically significant increase in naloxone 
prescriptions (p = 0.10) compared to those who did not receive the intervention, IRR 11.0, 95% 
CI [1.8, 67.8]. 
Behar et. al (2017) concluded that academic detailing addressing opioid safety and 
naloxone prescribing, was not only well-received by primary care providers who received it, but 
also significantly increased the naloxone co-prescription rates compared to those who did not.  
The findings supported that naloxone academic detailing can be an effective method to improve 
naloxone co-prescribing rates among primary care providers. Thus, this study provided 
evidence to support this DNP project. 
Level II Evidence 
 Bounthavong et al. (2017) conducted a good quality (B rating) study to evaluate the 
effects of an academic detailing service given to prescribing providers on naloxone co-
prescription rates between October 2014 to September 2016 in the Veterans’ Affairs.  Their 
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retrospective, repeated measures cohort study evaluated 750 primary care providers who had 
received at least one academic detailing (AD) service during the study period.  Academic 
Detailers were trained clinical pharmacists who provided individualized, face-to-face interactions 
to deliver evidenced-based-research, data tools and educational materials in an effort to change 
prescribing behaviors and promote guideline adherence.  Providers may have been aware of 
OEND programming but were categorized as unexposed until an AD training occurred.   
Of the 3313 providers, 22.6% received at least one OEND specific AD visit.  While the 
authors did not include raw data reporting, they did conclude that after one year, the average 
number of naloxone prescriptions showed a statistically significant increase (p < .001) in the 
exposed group than the unexposed providers with IRR 3.2, 95% CI [2.0, 5.3].  At two years, the 
average number of naloxone prescriptions continued to demonstrate a statistically significant 
increase (p < .001), again with a IRR 7.4, 95% CI [3.0, 17.9].  Although the authors pointed out 
that it was likely that an increased awareness of OEND programs grew during this period, 
naloxone prescribing from baseline to two years in the AD exposed providers still exhibited a 
7.1% higher average compared with AD-unexposed providers (95% CI [2.0%, 12.5%]).  
 Bounthavong et al. (2017) concluded that although AD interventions have been 
successful in other attempts to align provider compliance to guidelines (e.g., hypertension or 
judicious use of antibiotics), this was the first study that supported AD for OEND in primary care 
settings.  The findings supported that naloxone academic detailing can be an effective method 
to improve naloxone co-prescribing rates among primary care providers. Thus, this study 
provided evidence to support the intervention used within this DNP project. 
 Coffin et al. (2016) conducted a high quality (A rating) study evaluating the effects of a 
non-randomized intervention on naloxone co-prescription for primary care patients receiving 
long-term opioid therapy for pain.  This study took place between February 2013 to April 2014 in 
the San Francisco area, among six safety net clinics which had reported deaths from opioid 
related overdose between 2010 to 2012. 
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 At each of the sites, an “onsite leader” or champion was selected to deliver a consistent 
protocol which began with academic detailing for providers.  This detailing included rationale 
and indications for prescribing naloxone, appropriate language to approach patients to reduce 
stigma, naloxone formulations and pharmacy/payor coverage.  Providers and staff were also 
educated on how to train patients and family members on naloxone use and how to recognize 
an opioid overdose.  Training was provided approximately 30 days prior to the initiation of 
naloxone co-prescribing.  After the initiation of the naloxone co-prescribing program, additional 
training and at least one follow-up email were also completed.   
 Of the 1985 patients receiving long term opioids, 38.2% (n = 759) were given a naloxone 
co-prescription during the 2-year study.  Naloxone co-prescribing was not implemented at the 
clinics until the start of the study; therefore, none of the patients had previously received a 
naloxone prescription.  Although more extensive statistical review of data was completed 
regarding decreases in emergency department visits and daily MME changes, the authors did 
conclude that naloxone could successfully be prescribed in a primary care setting.  Providers 
who were given an AD session were advised to offer naloxone to all patients receiving opioids; 
however, many providers still prioritized naloxone co-prescribing to patients with higher 
established risk factors.  Despite this finding, the authors also concluded that providing 
naloxone through a primary care setting may have ancillary benefits, such as reducing opioid 
related deaths. 
 Coffin et al. (2016) concluded that the use of a clinical champion who conducted 
naloxone academic detailing sessions in the primary care setting could be an effective method 
to increase naloxone co-prescribing.  Thus, this study provided additional evidence to support 
the intervention and targeted outcomes for this DNP project. 
Level III Evidence 
 Behar et al. (2016) explored the acceptability of naloxone co-prescriptions among 
primary care providers who were treating patients on long-term opioid therapy for pain.  Behar 
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et al., in collaboration with Coffin et al. (2016), administered surveys electronically four to eleven 
months after Coffin et al.’s naloxone co-prescribing initiative began.  These surveys were 
distributed to providers in six San Francisco safety net clinics, which via Coffin’s et al. (2016) 
intervention, received at least one AD session prior to the initiation of naloxone co-prescribing 
practices within those clinics.  Nearly 70% of all providers receiving training in the Coffin et al. 
study (111 of 176) completed the survey.  Results indicated that the majority of responding 
providers (79.3%) had prescribed naloxone since the initiative began, and almost all (99.1%) 
indicated that they would be “somewhat to very likely” to prescribe naloxone in the future.  
Providers reported a willingness to prescribe to an expanded number of subgroups, including 
those on either high dose (>20 MME) or low dose (<20 MME) opioids (97.7% and 59.8%, 
respectively), the elderly, and those without a history of previous overdose.   
 This good quality (level A rating) study supported the premise that providers are willing 
to prescribe naloxone after they receive the AD (the intervention used within Coffin et al., 2016), 
and the researchers identified areas which need to be further addressed, through additional AD 
or via other means.  Behar et al. (2016) noted that the Coffin et al. intervention was completed 
before the release of newer CDC guidelines for safe opioid prescribing (CDC, 2016a) and 
therefore, the Behar et al. (2016) responses were truly reflective of the AD Coffin et al. (2016) 
provided.   
The study findings supported evidence that providers in a primary care setting could 
increase their willingness to prescribe naloxone after receiving an academic detailing session 
and, thus, AD could be an effective method to improve naloxone co-prescribing rates among 
primary care providers. Therefore, this high quality (grade A) study provided additional evidence 
supporting the creation of a coalition within the team-based approach of the Kotter model used 
within this DNP project. 
 Winograd et al. (2017) published a good quality (B rating) study conducted within the 
Veteran’s Health Administration (VHA) that aimed to answer three questions: (a) How 
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knowledgeable and comfortable are providers regarding the clinical incorporation of OEND? (b) 
If providers have concerns, what is their nature and magnitude? and (c) Does knowledge or 
concern vary by practice setting and profession?  Surveys were administered to prescribing 
providers within the VHA system prior to an AD session regarding OEND.  Each of these 
sessions, lasting 25 to 40 minutes, included a brief review of current overdose death rates and 
trends, overdose risk factors, and preventions methods, naloxone rescue devices, guidance on 
OEND patient trainings, theoretical and practical barriers as well as strategies for successful 
implementation.   
Forty-five participants including physicians, psychiatrists, residents, and “non-physicians” 
(nurse practitioners, physician assistants and clinical pharmacists), completed the survey. Prior 
to the AD session, results indicated that providers were more concerned with potential negative 
consequences of OEND implementation, and they were less concerned about unsafe opioid 
prescribing practices.   
Winograd et al. (2017) noted that after the OEND training was presented, prescriptions 
rates rose 331%, while the total prescribers of naloxone increased 323% compared to the 10-
month period prior to the OEND training.  The researchers stated, “although any relationship 
between training and increased prescription rates should of course be interpreted with extreme 
caution in the absence of data linking training attendees to their prescribing patterns, these 
changes may at least partially reflect the impact of the in-services” (p. 138.). 
Winograd et al. (2017) concluded that OEND training appeared to be associated with 
increasing rates of naloxone prescribing as well as increasing the number of actual prescribers.  
They further noted that the findings provided evidence for the need of increased OEND 
implementation efforts among settings where opioids are prescribed, particularly primary care 
settings.  The findings, within this good quality (B rating) study, supported that naloxone 
academic detailing can be an effective method to improve naloxone co-prescribing rates among 
primary care providers.  
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Level IV Evidence 
 Alexander et al. (2015) provided high quality (grade A) recommendations for an 
evidence-based approach to combat the prescription opioid epidemic.  The authors of this 
consensus, from the well-known leader in research and evidence-based practice Johns 
Hopkins, met with experts from a multitude of disciplines for a town-hall style meeting where 
they reviewed available evidence and developed three guiding principles for actionable 
recommendations.  Applicable to this DNP project, the clinical experts discussed the role of 
OEND programs in promoting appropriate and safe use of prescription opioids.  
Consistent with the strategy developed for this DNP project, the experts recognized that 
the actionable strategy was to engage health care providers to advance the co-prescription of 
naloxone.  Their recommendations supported the role of a clinical champion for naloxone as an 
effective method to improve naloxone co-prescribing rates among primary care providers.  
Level V Evidence  
A good quality (B rating) pilot project, led by Delaney et al. (2016) sought to increase 
naloxone co-prescription rates among four primary care offices in western Connecticut.  This 
quality improvement (QI) project had two primary objectives: (a) to increase the number of 
naloxone co-prescriptions written and (b) to explore best practices in developing a co-
prescription program in a primary care setting. 
The authors first examined baseline rates of naloxone prescriptions by reviewing EHR 
records.  A clinical champion, either a third-year resident or a clinician educator, created a log of 
all patients that would be eligible for naloxone co-prescriptions.  When patients presented to the 
clinic for scheduled refills from February to April 2015, the eligible patient was approached by 
the person who maintained the log and offered a pre-determined naloxone co-prescription. If the 
patient stated he or she was interested, an additional appointment was scheduled for a patient 
teaching session prior to the prescription being provided.   
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Baseline data revealed that zero naloxone prescriptions had been written prior to the 
beginning of the QI project.  Following the intervention, among the four clinics, approximately 
26% of identified individuals were given a naloxone co-prescription.  While the QI project did 
produce positive outcomes, the authors noted that they encountered several barriers, and as a 
result, they provided several recommendations for other practices wishing to implement 
naloxone co-prescribing.  Notably, the relevant recommendation to this DNP project included 
establishing a provider champion at each site (Delaney et al., 2016).   
Delaney et al. (2016) concluded that the use of a clinical champion in a primary care 
setting was an effective way to increase naloxone co-prescriptions.  Thus, this study provided 
evidence to support the intervention for this DNP project, but also provided additional 
information regarding targeted outcomes and anticipated barriers to implementation. 
Consistent with more recent quality improvement initiatives to address the opioid crisis, 
Devries et al. (2017) (high quality, level A rating) implemented a program to increase OEND 
within the University of California San Diego Health System.    This health system serves as the 
San Diego County safety net hospital and includes 563 hospital beds and 6 pharmacies, with a 
total of 636,118 outpatient visits in 2015.  Their goal, to increase take-home naloxone with the 
ultimate goal of preventing fatalities, focused on AD for providers, dissemination of patient 
education materials, EHR changes to promote naloxone prescriptions, and availability of 
naloxone in pharmacies.  AD was provided via departmental trainings lasting 15 to 60 minutes, 
posting of bulletins, and email notifications. Training included criteria for prescribing, 
epidemiology of opioid overdose and health disparities, evidence for naloxone distribution, 
methods of naloxone administration, EHR steps for prescribing, and related prescribing and 
liability laws.  The training was provided to 252 of 905 eligible physicians, pharmacists, nurses 
and pharmacy technicians, including 184 of 533 eligible providers with prescriptive authority. 
These combined efforts resulted in 245 doses of naloxone being co-prescribed between 
January and October 2016.  This intervention increased the baseline rate of naloxone co-
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prescriptions ten-fold from 4.5 per month to an average of 46 per month in the three months 
following full implementation.   
Devries et. al (2017) concluded that academic detailing addressing opioid safety and 
naloxone prescribing, in conjunction with patient education materials and EHR changes 
significantly increased the naloxone co-prescription rates.  Devries et al. (2017) recommended 
continued training for providers and the development of a script to assist with difficult patient 
conversations regarding naloxone use.  The findings supported that naloxone academic 
detailing (which included provider training and reminders) can be an effective method to 
improve naloxone co-prescribing rates among primary care providers. Thus, this study provided 
additional evidence regarding length of time for the AD and EHR reminders to support the 
intervention in this DNP project. 
As the first major health system to translate a public health community based OEND 
approach to a health care system approach, Oliva et al. (2017) (high quality, A rating) examined 
the effects of a system-wide quality improvement program to launch the development of a 
national opioid OEND program within all 142 VHA facilities.  Their concentration was on 
developing clinical guidance for issuing naloxone kits as well as developing focal campaign of 
AD.  Their program processes included seven steps, the first being to establish at least one 
clinical champion at each facility to speed OEND implementation.  This clinical champion then 
worked with leadership to develop an overall OEND roll-out implementation plan.  VHA 
leadership also recommended that the clinical champion determine what material, resources, 
and protocols were necessary. By doing this, the clinical champions would garner support for 
overall project success.   
As the processes continued, Oliva et al. (2017) reported that VHA efforts varied in the 
AD of their providers, from individual training of staff by the clinical champion to community 
partners and train-the-trainer models. It was also deemed important to leverage existing staff 
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and resources to implement OEND to patient populations by using brochures, mailing flyers, 
and displaying posters to increase overall awareness of programming. 
Between October 2015 to September 2016, VHA AD services completed more than 
3900 individualized evidence-based OEND education outreach visits and has had consultation 
with more than 7000 VHA providers. Although no written baseline data was provided, a graph 
depiction embedded in the article indicated a sharp quarterly rise in naloxone prescriptions 
dispensed beginning in the first quarter of 2015, the time indicated as the first documented 
national AD session.   By the end of fiscal year 2016, 5693 VHA providers had written a total of 
45,178 naloxone prescriptions for 39,328 patients.  
Although much of the original program continues as was originally designed, Oliva et al. 
(2017) noted that naloxone co-prescribing practices have been amended to include one refill, so 
patients always have access to naloxone in case of an emergency.  Further, they opined that 
AD can play a critical role in facilitation of OEND implementation.  “Medical facilities should 
consider developing academic detailing programs to maximize the benefits in achieving optimal 
OEND implementation and sustainability.” (Oliva et al., 2017, p. S176). 
Additional lessons learned from this system-wide program address the importance of 
engaging patients, leaders, and staff across the clinical setting.  Oliva et al. (2017) also noted 
that having a champion with dedicated time to support and facilitate OEND implementation is 
ideal.  This study supported the use of a clinical champion with time to develop and administer 
patient education materials in addition to the delivery of AD sessions to clinical staff as an 
effective way to increase naloxone co-prescriptions.   
Similar to the work in the VHA system, Wilson et al. (2017) drew upon the best available 
evidence to design and implement a targeted naloxone co-prescribing program within a large 
academic family medicine practice in western North Carolina.  Their project used a pharmacist, 
who manually reviewed the EHR and identified those meeting criteria for naloxone co-
prescriptions, as the clinical champion. The clinical champion then provided an AD session to 
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providers which covered four main topics. First, opioid epidemic awareness focused on national 
and local statistics of the opioid epidemic, a harm reduction approach, the role of naloxone as 
an opioid overdose reversal agent, and previous successes with community-level distribution of 
naloxone.  The second topic addressed emergency management, including overdose 
recognition and what to do when an overdose is witnessed.  The third focus (naloxone 
administration) discussed formulations of naloxone, directions for use, onset of action, and 
when to re-dose.  Finally, financial considerations (e.g., insurance coverage of naloxone 
formulations and billing for clinical encounters when prescribing naloxone) were covered. 
Wilson et al.’s (2017) baseline data indicated that 709 of the audited 1297 patients were 
identified as chronic opioid users; 350 of the chronic users (49.4%) met criteria for naloxone co-
prescriptions, but only 3.4% had naloxone on their medication list.  The program took four 
months to develop and implement, achieving full implementation in September of 2016.  It is 
notable that this project evaluation planned assessments at 3-, 6-, 12- and 18-months post-
implementation.  Thus, although this project was fully implemented on September 2016, Wilson 
et al. (2017) noted that the manuscript was submitted for publication in August 2016, making it 
impossible to discuss the impact of these interventions (Wilson et al., 2017). 
Although this piece of evidence did not yet have results available thus earning a low 
quality (C rating), the authors did outline a systematic evidence-based approach for increasing 
naloxone co-prescriptions within a family practice.  Wilson et al. (2017) determined that the use 
of a clinical champion within the clinical setting, who developed and delivered an AD session, 
was the most likely to have the desired outcomes.  Thus, this piece of evidence provided 
additional support for the use of a clinical champion and AD sessions as a best practice for 
increasing naloxone co-prescribing. 
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Construction of Evidence-based Practice 
Synthesis of Critically Appraised Literature 
A major focus identified throughout the reviewed literature was that current available 
research on naloxone co-prescribing and effective interventions to promote co-prescribing is 
rapidly changing (Alexander et al., 2015; Behar et al., 2016; Behar et al., 2017; Bounthavong et 
al., 2017; Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017; Oliva et al., 2017; Wilson 
et al., 2017; Winograd et al., 2017). Within both the health care and private sectors, an 
increased awareness of the purpose and availability of naloxone has become apparent. As a 
result, many health care facilities are facing the issue while operating in crisis mode as they 
attempt to implement EBP strategies to increase access to naloxone.  Thus, there is a need for 
the dissemination of additional evidence from EBP projects to reinforce best practice.  
Although the systematic literature review highlighted the effects of multi-faceted 
strategies to improve naloxone co-prescribing, the most commonly incorporated elements were 
the use of AD and clinical champions (Alexander et al., 2015; Coffin et al., 2016; Winograd et 
al., 2017; Wilson et al., 2017).  Not surprisingly, the literature review indicated that providers 
were more likely to co-prescribe naloxone if their level of knowledge about doing so was 
increased, and AD sessions were well-documented as an effective means of enhancing practice 
change (Behar et al., 2016; Behar et al., 2017; Bounthavong et al., 2017; Coffin et al., 2016; 
Delaney et al., 2016; Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017; Winograd et al., 
2017).    
AD sessions carried common themes of rationale and indications for prescribing 
naloxone, available naloxone formulations, acquisition and payment information as well as 
strategies to initiate and carry out education to patients (Alexander et al., 2015; Coffin et al., 
2016; Winograd et al., 2017; Wilson et al., 2017).  Early reviews of several pilot programs using 
a multi-faceted approach included the use of AD intervention (Behar et al., 2016; Delaney et al., 
2016; Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017).  While the facilitators of these 
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programs acknowledged that many of their results were preliminary, reports of early findings 
included positive outcomes.  
The use of a clinical champion within the practice setting was another commonly 
included intervention within multifaceted interventions (Alexander et al., 2015; Coffin et al., 
2016; Winograd et al., 2017; Wilson et al., 2017).  Clinical champions were able to increase the 
pace at which OEND programs could be successfully implemented into a practice change; the 
use of a clinical champion was also instrumental for determining or developing an appropriate 
protocol, identifying or developing training and materials for distribution, and working with 
leadership to facilitate a smoother roll-out process. Although not all evidence was specific on the 
clinical educational background of the champion, some supported the use of a pharmacist or 
another prescribing provider (Wilson et al., 2017).   
Additional components of the multifaceted interventions included the use of provider 
reminders (e.g., alerts within EHR) (Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017). 
While other researchers addressed enhancing the accessibility of the physical naloxone 
prescription (Alexander et al., 2015; Behar et al., 2016; Coffin et al., 2016; Delaney et al., 2016; 
Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017).  
All the pieces of evidence reviewed acknowledged that the issue at hand, naloxone co-
prescriptions, could not be successful with the utilization of a solitary intervention (Alexander et 
al., 2015; Behar et al., 2016; Behar et al., 2017; Bounthavong et al., 2017; Coffin et al., 2016; 
Delaney et al., 2016; Devries et al., 2017; Oliva et al., 2017; Wilson et al., 2017; Winograd et al., 
2017). Thus, a multifaceted approach was deemed appropriate.  
Best Practice Model Recommendation 
Utilizing appraised literature was the foundation for this EBP project.  The DNP student 
facilitator presented the evidence synthesis to the CS task force and conferred with the team to 
determine the best practice recommendations that were applicable to the project facility.  The 
review and synthesis of the best available evidence provided the solid foundation that was 
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needed to answer the clinical question and develop a PICOT question when using the Iowa 
model for EBP: Among primary care providers in a tribal health clinic, does the introduction of 
an multi-faceted intervention, which includes the use of academic detailing and a clinical 
champion, versus the current practice of no intervention, improve the co-prescription rates of 
naloxone to chronic opioid patients in a twelve week period? 
How the Best Practice Model Will Answer the Clinical Question 
Results and evidence for the literature synthesis provided the structure for the 
development of a multi-faceted OEND intervention.  An AD session, which gave step by step 
instructions for the logistics of dispensing naloxone within the primary care clinic was 
developed.  Clarity regarding who would order and maintain available naloxone stock was 
attained.  A clinical champion was selected (DNP student facilitator) and OEND educational 
materials were procured for provider AD sessions; patient education brochures for distribution 
during clinic visits and posters for waiting and exam rooms were made available to spark 
conversation.  AD sessions were held in a group format and additional group follow up and one- 
on-one sessions were completed when appropriate. 
Utilization of the Iowa model incorporates teamwork and collaboration, which was felt to 
be a fundamental property to the implementation of this EBP project.  The Iowa model was 
especially useful in identifying systems problems and investigating potential interventions which 
complemented the first three steps of Kotter’s change model and mandated input from the task 
force.  The team-based dialogue allowed for open communication to voice concerns and 
address potential unforeseen barriers to naloxone co-prescribing.  The team then determined 
that the multifaceted approach was warranted but recognized the limited applicability of alerts 
within the EHR and the potential barriers for the accessibility of the prescription. The barrier of 
accessibility was overcome by stocking the naloxone within the clinic.   Although, the EHR was 
not used to provide patient alerts, the team worked with the CAC to imbed order sets to 
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dispense naloxone and provide education in an effort to ease time constraints during clinic 
visits.   
This team-based approach also allowed the facilitation and communication of Kotter’s 
fourth step, understanding of goals.  Kotter’s fifth step was addressed when an action plan was 
developed using the best practice suggested by the DNP student facilitator that would lead to a 
demonstration of improved naloxone co-prescribing as evidenced by an increased number of 
naloxone prescriptions being distributed.   
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Citation 
Design/Level/ 
Quality Rating 
Setting/Sample Intervention(s) Outcomes/Measures Findings 
Alexander, 
Frattaroli, & 
Gielen (2015) 
 Consensus 
Statement 
 Level IV 
 Grade A 
 Community 
stakeholders 
 Pharmacy staff 
 Medical 
community 
 Develop evidence- 
based consensus 
statement 
 3 guiding 
principles 
developed 
 1 relevant to 
project: promoting 
appropriate and 
safe use of 
prescription 
opioids 
 
 Engage with providers to 
advance the co-
prescription of naloxone 
with prescription opioids 
 Behar et al. 
(2016) 
 Descriptive, 
correlational, 
retrospective 
study 
 Level III 
 Grade A 
 
 6 safety net 
clinics in San 
Francisco 
 111 Providers  
 Naloxone co-prescribing 
training 
 Providers received 3 
focused follow up 
sessions (rationale and 
indications for 
prescribing naloxone, 
available naloxone 
formulations, insurance 
coverage information 
and communication 
strategies around 
discussing naloxone with 
patients) 
 Email reminders sent to 
providers to remind them 
about naloxone co-
prescribing 
 Explore naloxone 
co-prescribing in 
primary care 
setting after 
trainings 
 79.3% of providers who 
received the AD session 
prescribed naloxone (no 
co-prescribing in place 
prior to intervention) 
 99.1% were likely to very 
likely prescribe naloxone 
in the future 
 59.8% likely to prescribe 
to those receiving low 
doses (< 20 MME daily) 
 83.9% likely to prescribe 
to > 65 years old 
 80.7% likely to prescribe 
to those with no overdose 
history 
 73.6% with no SUD 
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Citation 
Design/Level/ 
Quality Rating 
Setting/Sample Intervention(s) Outcomes/Measures Findings 
Behar et al. 
(2017) 
 RCT 
 Level I 
 Grade B 
 40 randomly 
selected opioid 
prescribing 
primary care 
providers in the 
San Francisco 
Area 
 Providers received 
detailing regarding 
naloxone prescribing for 
5-60 minutes  
(m = 28 minutes) 
 Most frequently covered 
topics included: 
indications for naloxone, 
examples of naloxone 
prescriptions, language 
to use with patients, and 
pharmacy outreach 
 Changes in rates 
of naloxone 
prescriptions, 
comparison 4 
months before and 
after providers 
received academic 
detailing of 
naloxone 
prescribing 
 Naloxone co-
prescriptions filled by 
patients increased from 0 
to 10 among those that 
had been seen by a 
provider who received 
detailing vs. by the 
providers who did not 
receive detailing (IRR = 
11.0; 95% CI [1.8, 67.8], 
p = 0.010) 
 
Bounthavong 
et al. (2017) 
 
 Retrospective 
repeated 
measures 
cohort study 
 Level II 
 Grade B 
 VA providers 
who were 
actively treating 
patients in 
family practice 
or substance 
use disorder at 
time of study 
 A total of 750 (22.6%) 
out of 3,313 providers 
received at least one 
OEND-specific AD visit 
 
 Evaluate the 
impact of 
academic detailing 
on naloxone co-
prescribing 
 Naloxone co-prescribing 
rate (from baseline to 2 
years) was 7.1% greater 
in the AD exposed 
providers (95% CI = 
2.0%, 12.5%) compared 
to the AD-unexposed 
providers 
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Citation 
Design/Level/ 
Quality Rating 
Setting/Sample Intervention(s) Outcomes/Measures Findings 
Coffin et al. 
(2016) 
 Quasi-
experimental 
 Level II 
 Grade A 
 6 safety net 
clinics in the 
San Francisco 
area 
 1985 adults 
receiving long-
term opioid 
therapy for pain 
 Onsite leader selected 
 Clinic staff received 
training in naloxone 
prescribing (including 
rationale and indications 
for prescribing, language 
to approach patients, 
naloxone formulations 
and pharmacy/payor 
coverage) 
 Staff trained how to 
educate patients about 
naloxone use and 
assembly of naloxone 
device 
 Follow up training 
provided 
 At least one reminder 
email sent to providers 
 
 Proportions of 
patients 
prescribed 
naloxone, opioid-
related emergency 
visits and 
prescribe opioid 
dose based on 
chart review 
 759 (38.2%) of 1985 
eligible patients were co-
prescribed naloxone 
during intervention 
 No net change in opioid 
dose over time between 
those that received 
naloxone prescription 
and those who did not 
(IRR = 1.03, 95% CI = 
0.91-1.27, p = 0.61) 
 Delaney et 
al. (2016) 
 QI project 
 Level V 
 Grade B 
 4 primary care 
offices in 
western 
Connecticut 
serving as 
medical home 
training sites 
for primary care 
residents 
 All patients on 
chronic opioid 
therapy 
screened for 
eligibility 
 2-month period 
 Signage placed in 
check-in areas of 
patients indicating 
naloxone was available 
 QI safety initiative, those 
eligible for naloxone co-
prescriptions identified 
and approached by 
residents who were 
given scripting for 
encounter 
 
 Rate of naloxone 
co-prescriptions 
written 
 
 Training sites increased 
naloxone co-prescription 
rates from 0 to 53 of 204 
(26%) eligible patients 
 3 sites dispensed (n = 3, 
N = 64) naloxone 
prescriptions, where 
opioids were managed by 
pain specialists; the 4th 
site managed opioids by 
the primary care and 
dispensed a higher 
percentage of naloxone 
(n = 50, N = 140) 
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Citation 
Design/Level/ 
Quality Rating 
Setting/Sample Intervention(s) Outcomes/Measures Findings 
Devries et al. 
(2017) 
 
 
 Program 
Evaluation 
 Level V 
 Grade A 
 Multisite 
academic 
health system 
in California 
 Implement a naloxone 
distribution program  
 Staff member were 
given trainings lasting 15 
minutes to 1 hour that 
covered 
epidemiology of 
overdose, evidence for 
naloxone distribution, 
methods of naloxone 
administration, criteria 
for prescribing, EHR 
steps for prescribing and 
related prescribing and 
liability laws 
 PowerPoint training was 
made available to staff 
who could not attend 
 
 Rate of naloxone 
co-prescriptions 
written 
 
 Naloxone prescription 
rates increased from 4.5 
per month to 46 per 
month following full 
implementation, 
indicating a 10-fold 
increase 
 Physicians wrote 85.3% 
(n = 209, N = 245) 
 NP wrote 9.8% (n = 24, N 
= 245) 
 PA wrote 3.7% (n = 9, N 
= 245) 
 Pharmacists wrote 1.2% 
(n = 3, N = 245) 
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Citation 
Design/Level/ 
Quality Rating 
Setting/Sample Intervention(s) Outcomes/Measures Findings 
Oliva et al. 
(2017) 
 Program 
Evaluation 
 Level V 
 Grade A 
 VHA medical 
facilities 
nationwide (N = 
142) 
 Implement OEND 
nationwide 
 
 Pharmacy 
development of 
naloxone rescue 
kits 
 Developing clinical 
guidance for 
issuing kits 
 Supporting OEND 
as a focal 
campaign of AD 
 VHA dispensed 45,178 
naloxone prescriptions in 
2016 by 5693 prescribers 
to 39,328 patients 
 Initial VHA pilots varied in 
their training process, 
ranging from individual 
training by clinical 
champion to training of 
staff by community 
partners and train-the-
trainer models. 
 Recommendations 
included:  
 Have a champion with 
dedicated time to support 
and facilitate OEND 
implementation. 
 Establish at least one 
clinical champion at each 
facility to help speed 
OEND implementation. 
 Clinical champion should 
work with leadership to 
develop OEND 
implementation plan 
 Consider using AD 
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Citation 
Design/Level/ 
Quality Rating 
Setting/Sample Intervention(s) Outcomes/Measures Findings 
Wilson, 
Rodriguez, 
Carrington, & 
Fagan. (2017) 
 Program 
Evaluation 
 Level V 
 Grade C 
 Large 
academic 
family medicine 
practice in 
North Carolina 
 n = 350 (N = 
709) patients 
met CDC 
criteria for 
naloxone 
prescribing  
 n = 12 had 
naloxone on 
their 
medication list 
prior to 
implementation 
 Develop a targeted 
naloxone co-prescribing 
program in a primary 
care practice through 
use of a clinical 
champion 
 Sequential concurrent 
three phase rollout: 
 Phase one: Pharmacists 
(clinical champion) 
embedded in practice 
provided academic 
detailing 
1. Opioid epidemic 
awareness 
2. Emergency 
management 
3. Naloxone 
administration 
4. Financial 
considerations 
 Phase two: Logistical 
barriers to prescribing 
naloxone were 
addressed 
 Phase three: Barriers 
related to patient 
engagement addressed 
 
 Improve naloxone 
co-prescriptions 
rates 
 Program in progress 
 Article was received for 
submission August 31, 
2016, program was fully 
implemented September 
2016.  Authors address 
that next steps include 
determining how many 
patients identified 
actually received 
naloxone prescription.  
Assessments planned at 
six, twelve and eighteen 
months. 
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Citation 
Design/Level/ 
Quality Rating 
Setting/Sample Intervention(s) Outcomes/Measures Findings 
Winograd, 
Davis, 
Niculete, 
Oliva, & 
Martielli. 
(2017) 
 Descriptive 
study 
 Level III 
 Grade B 
 
 Convenience 
sample of 
prescribers 
within the 
Veterans 
Affairs health 
system  
 n = 45, N = 54 
 Non-interventional 
 Surveys completed by 
prescribing providers to 
obtain baseline 
knowledge and concerns 
prior to attending OEND 
education training  
 Determine how 
knowledgeable 
and comfortable 
are providers 
regarding the 
clinical 
incorporation of 
OEND 
 Determine if 
providers have 
concerns, what is 
their nature and 
magnitude? 
 Determine if 
knowledge or 
concern vary by 
practice setting 
and profession. 
 Concerns of iatrogenic 
effects of OEND were 
rated higher than 
concerns about 
impressions of unsafe 
prescribing practices 
(t(42) = 3.06, p < .01) 
 Endorsement of lack of 
knowledge/familiarity/com
fort (t(42) = 3.91, p < 
.001)  
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
Naloxone co-prescriptions are recommended as a risk mitigation strategy in opioid 
prescribing, yet there is still a nationwide struggle to gain acceptability of universal prescribing in 
primary care settings (CDC, 2016a).  Despite recommendations by governing bodies and 
agencies targeting the opioid epidemic, there remains a wide gap between naloxone co-
prescriptions practices and provider adherence to guidelines (CDC, 2016a; IHS, 2015; 
USDHHS, 2016) 
Participants and Setting 
The focus of this DNP project was to implement a multifaceted intervention, which 
included an academic detailing program, provider reminders, and the utilization of a clinical 
champion, to improve rates of naloxone co-prescribing within a primary care setting.  The 
project was initiated among an Indian Health Service Tribal Health Department with one  
satellite locations in a rural setting and one an urban setting; these facilities will furthermore be 
referred to as Clinic X.  A third satellite location, within an occupational setting, was not included 
in the project data as that facility typically did not see a patient population which received 
chronic opioids, and the DNP student facilitator was also the primary provider at that location.  
Thus, excluding patients seen at this venue removed the potential selection bias that may have 
skewed outcome data in this EBP project. 
While in separate geographic locations, the clinics had attempted to standardize practice 
across the settings and utilize evidence-based medicine whenever possible.  Although clinic 
providers typically remained stationed at one location, all were cross-trained to work in any of 
the settings.  Many of the support staff and other departments worked among all the clinics on a 
routine basis.   
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Within the Indian Health Services Tribal Health Department, the governing tribal council 
had deemed the opioid epidemic a priority and implemented a policy to assist with the 
distribution of naloxone to at-risk tribal members and clinic utilizers.  Despite this, the tribal 
health department providers had vocalized concerns at regularly scheduled staff meetings 
regarding current best-practice evidence for both opioid prescribing and naloxone distribution.  
A recently revised mission statement which focused on quality, integrated patient centered-care 
prompted the review of current prescribing practices to determine if what was presently utilized 
was in fact, current best practice. 
Offering a wide variety of primary care services including pain management, the clinics 
were well-appointed to determine if a multi-faceted approach would increase naloxone co-
prescriptions to patients who were prescribed long-term (30 days or longer) opioid medications.  
The clinics were staffed by providers of a variety of health care disciplines, with prescribing 
providers including one full-time PA in the rural location, one full-time PA in the urban location, 
one NP (DNP student facilitator) in the occupational setting and two physicians: one working 
full-time and rotating through each clinic location and the medical director who works one day 
per week, rotating clinical sites.  The medical director provided oversight to the advanced 
practice clinicians and assisted with complex patient management, including those who were 
prescribed controlled substances.  Aligning well with the Iowa model, in a team format, all 
providers verbally gave support to proceed with a project that would assist with furthering the 
goal of safe opioid prescribing and management.   
Pre-Implementation Data 
Clinic X provided services to 48 eligible patients receiving chronic opioid prescriptions 
(30 days or longer) between September 25th, 2016 through December 15th, 2017.  None of 
these patients were found to have received a naloxone prescription during this period. Nearly 
two-thirds of these patients were females (66.7%, n = 32) and the remaining 16 patients being 
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males (33.3%).  The slight majority of patient were seen in the urban clinic (58.3%, n = 28), 
while the rural clinic provided services to the other 41.7% (n = 20). 
 
Outcomes 
 This EBP project examined how a multifaceted intervention, utilizing a clinical champion 
who provided an academic detailing session and intermittent formal and informal follow-up 
(provider reminders) to the prescribing providers could influence naloxone co-prescriptions.   
Additionally, during the primary formal academic detailing session, printed materials were 
distributed. The printed materials served two purposed: (a) references for prescribing providers 
and (a) educational tools to be distributed to patients during clinic encounters.   The primary 
outcome of the EBP project was to measure the rates of naloxone co-prescriptions written to 
eligible clinic utilizers by primary care providers within the health care clinics during a 12-week 
period. Literature supported the use of a clinical champion to advocate for the use of naloxone 
co-prescriptions and provide the academic detailing session (Behar et al., 2016; Behar et al., 
2017; Bounthavong et al., 2017; Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017; 
Oliva et al., 2017; Wilson et al., 2017; Winograd et al., 2017).  Twelve weeks of pre-
implementation data were collected via retrospective chart review, for those patients who had 
received opioid prescriptions of 30 days or greater, from the corresponding period the year prior.  
Evaluating data from the same period the previous year helped to eliminate seasonal 
fluctuations of clinic usage and to prevent any prescribing practice changes that providers may 
have self-initiated during the planning stages of this DNP project.  This data was then compared 
to prescribing patterns twelve weeks during the implementation phase, a length chosen 
purposefully to align with recommendations from the CDC that patients receiving chronic opioids 
be re-evaluated every three months (CDC, 2016a).  This time frame provided the best scenario 
for being able to capture all eligible chronic opioid users during the intervention period.  For 
comparison of naloxone co-prescription rates collected during the pre-implementation phase 
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and implementation phase, chi-square analysis was utilized.  Based on evidence demonstrated 
from Delaney et al. (2016), a benchmark outcome of a 25% increase in naloxone co-prescribing 
rates would indicate project success.  Additionally, secondary analyses investigated 
relationships between patient demographics, provider adoption of co-prescribing, daily MME 
prescribed, concurrent benzodiazepine use, clinic location, and whether a clinic visit occurred 
for any reason during the data collection period.    
Planning and Intervention 
The implementation of the practice change and data collection was conducted over 
twelve weeks, from September 25, 2017 to December 15, 2017.  Consistent with Kotter’s eight-
step change theory, support from the clinical agency and key stakeholders was obtained early in 
the planning stages.  The clinical manager and prescribing providers contributed to the plan and 
provided verbal encouragement to the DNP student facilitator.  As planning proceeded, the 
project was divided into three phases.   The first phase being the pre-implementation phase 
where the DNP student facilitator collected data, procured educational materials, and developed 
the academic detailing session.  The second phase consisted of the implementation of the 
intervention, which included the presentation of the formal academic detailing session and 
clinical champion involvement.  The third and final phase consisted of post-intervention data 
collection and analysis. 
Following the approval of the IRB board from Valparaiso University, implementation and 
coordinating data collection began September 25, 2017.  A large portion of the preparatory work 
was completed by the DNP student facilitator via unpaid hours that also satisfied DNP program 
course requirements.  Development of the instrument design for data collection (Appendix A), a 
one-hour academic detailing session PowerPoint (Appendix B), provider naloxone prescribing 
guide (Appendix C), and patient naloxone educational pamphlet design (Appendix D), as well as 
procurement of educational posters (Appendix E) and adding the naloxone into the EHR for 
documentation of distribution in the clinic were all completed prior to implementation.  
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Additionally, with the assistance of the Clinical Applications Coordinator (CAC), an employee of 
the agency who assists providers and other clinic staff to optimize the utilization of the EHR and 
create, run, and distribution various reports in her normal job duties, baseline data of all current 
chronic opioid patients was obtained and reviewed for accuracy, which was later distributed to 
the appropriate ordering provider during the formal academic detailing session.  Consistent with 
Kotter’s short-term wins, the clinical champion provided project updates and status of naloxone 
distribution at regularly scheduled monthly provider meetings, planned email update at the mid-
way point and other informal individual contacts via phone, email, video conference and face-to-
face interactions.  The DNP student facilitator made efforts to ensure informal contacts occurred 
equally among prescribing providers so that naloxone adoption rates would not be influenced. 
 During the implementation phase, the providers, the registered nurse (RN) clinical 
manager, and the clinical support staff; consisting of two full time RNs and two full time medical 
assistants (MA), were provided the academic detailing session regarding naloxone co-
prescriptions during two separate sessions on September 25th and September 26th, 2017.  
Although originally planned to take place in a single session, so all members of the CS task 
force could be present, a scheduling conflict arose, and the session was therefore repeated the 
following day to capture those previously unable to attend.  The 1-hour session, conducted in 
the health department conference room at the rural location with simultaneous video-
conferencing to the urban location, consisted of a PowerPoint presentation adapted from 
educational materials previously developed by PrescribeToPrevent, a nationally recognized 
organization that published toolkits regarding opioid safety and overdose prevention resources 
for prescribers and pharmacists (PrescribeToPrevent, 2015).  The publications were widely 
available on the internet and were free for use. During this session, the following topics were 
addressed: (a) relevant opioid overdose statistics, (b) naloxone pharmacology, (c) current 
naloxone co-prescribing recommendations, (d) current organizational naloxone policy (which 
included stocking naloxone onsite and dispensing the medication prescribed the day of the 
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office visit versus returning for the for the education component), (e) proper naloxone 
administration (via a 7-minute video [an organizational policy requirement for patients being 
distributed naloxone]), and (f) procedures for EHR documentation.  A packet containing a copy 
of the PowerPoint slides (Appendix B), the current CDC prescribing clinician pocket reference 
(Appendix F), naloxone product comparison sheet (Appendix G), a fact sheet from the 
manufacturer of the naloxone product purchased for distribution (Appendix H), and a quick start 
guide for the same naloxone product (Appendix I) were provided to all participants.  Additionally, 
each prescribing provider received an individualized report compiled by the CAC that listed all 
patients who had received an opioid, benzodiazepine, or naloxone prescription in the 90 days 
preceding the academic detailing session.   
The providers were advised to begin utilizing universal naloxone co-prescribing practices 
immediately and were encouraged to use the CAC provided list of their patients as a reference 
to capture those patients during any clinic visit that occurred during the intervention period, 
whether for an opioid related reason or for another reason, such as acute illness.  The DNP 
student facilitator was available throughout the implementation period for support or additional 
academic detailing as needed, which arose only as simple clarification questions regarding the 
distribution process, not the pharmacology or rationale for naloxone co-prescribing.  Consistent 
with Kotter’s short-term wins, a follow up email was sent by the clinical champion at the 6-week 
mark to remind providers of the ongoing intervention and to inform providers of interim data, 
including the number of prescribed naloxone dispensed thus far; this reminder intended to 
provide further motivation and prevent stagnation of the EBP project intervention.  The 
intervention was also discussed at the monthly provider meetings, providing another opportunity 
to discuss short-term wins (such as distribution success) and any provider concerns and 
barriers were addressed at that time.   
Clinical support staff, who also attended the academic detailing session, were 
responsible for the management of a naloxone distribution log as per organizational policy 
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(maintained in an electronic fob access formulary at each location).  Access was only available 
to providers, clinical support staff, and the clinical manager.  Support staff were also responsible 
for maintaining the supply of naloxone and reordering if stock became low.  Replacement stock 
generally arrived one business day after the order was placed. 
Posters obtained from PrescribeToPrevent.org (2015) (Appendix E) were placed in 
targeted vantage point locations of the waiting area, restrooms, and exam rooms. Additional 
information regarding the availability of naloxone at the clinic was included in an educational 
article written by the DNP student facilitator, published in the quarterly health publication, fall 
edition (Appendix J).  This publication was mailed to the homes of all current registered patients 
of the clinic and additional copies were widely available throughout the clinics in the waiting 
areas and exam rooms.  The original intention for these materials were for patient education; 
however, during the EBP project, they also served as visual reminders to the prescribing 
providers. 
 During the post-implementation phase, the DNP student facilitator calculated the 
outcomes measures, including the primary objective: naloxone co-prescription rate differences 
between the pre-intervention period and the intervention period.  Since the pre-intervention 
group was known not to have dispensed any naloxone co-prescriptions, secondary statistics 
were calculated solely on the intervention group.  To determine if relationships existed in the 
intervention group, demographics (including age, gender, daily MME, concurrent prescription of 
benzodiazepines clinic location and provider discipline) were evaluated.  
Data 
Collection 
 At the completion of the 12-week implementation period, a chart audit was conducted to 
determine the percentage of eligible patients prescribed naloxone. This was done with the 
assistance of the CAC, who, within her usual job duties, generated reports from the Resource 
and Patient Management System EHR used by the clinics.  Reports regarding co-prescriptions 
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of naloxone as well as current opioid prescriptions written were then verified by the DNP student 
facilitator for accuracy and cross-referenced with the naloxone distribution log maintained by the 
clinical support staff to ensure complete data capture.  Based on the reports generated by the 
CAC, 48 EHR records were audited pre-implementation and 40 EHR records were audited from 
the implementation period.   Demographics regarding mean age, gender, primary diagnosis, 
tribal affiliation, concurrent benzodiazepine prescriptions, and daily MME of opioid dosing were 
also collected to evaluate if there were any differences in the proportion of naloxone co-
prescriptions written based on these characteristics.  Additionally, whether the patient had a 
clinic visit during the intervention period, which clinic dispensed the naloxone, which provider 
dispensed, and whether the dispensed naloxone was recorded in the EHR correctly were further 
evaluated. 
 Informal bi-weekly review of the naloxone distribution log afforded the opportunity for 
continuous evaluation of study implementation.  This was provided by either a verbal report from 
the clinical support staff in each clinic or a visual review by the DNP student facilitator. 
Management and Analysis 
 SPSS Version 22 was utilized for data analysis.  Parametric statistics were conducted to 
test that providing academic detailing sessions via a clinical champion was associated with an 
increased rate of naloxone co-prescriptions dispensed within a primary care clinic setting.  In an 
effort to determine if further relationships existed in the intervention group, additional parametric 
and non-parametric testing was completed to evaluate statistical differences.   
Protection of Human Subjects 
 The student facilitator successfully completed the National Institutes of Health (NIH) 
protection of human rights training on February 28th, 2017 (Appendix K). To protect human 
rights and maintain compliance with HIPAA laws, identifying information (e.g., patient name and 
medical record number) was kept within the clinical setting and security was maintained in a 
locked cabinet, accessible only by the DNP student facilitator. The naloxone distribution log, as 
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per organization policy was securely maintained in an electronic fob access formulary which 
itself was located inside the providers’ office.  Electronic fob access was available only to the 
providers, clinical support staff, and clinical manager.  The office space itself was locked when 
not occupied by a provider.  During chart audits, EHR records accessible to the DNP student 
facilitator through authorization of her employment status, were conducted in the facilitator’s 
closed office when other staff members were not present, to ensure that protection of data was 
maintained.  No identifying data of individual patients was disclosed during the final report, as 
project data was reported in the aggregate form only. The student facilitator will maintain the 
records in this secure fashion for three years, at which time data will be destroyed by shredding.   
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CHAPTER 4 
FINDINGS 
This EBP project was designed to determine the effect of a multi-faceted intervention on 
the naloxone co-prescription rates among primary care providers, who prescribed chronic 
opioids to patients for 30 days or greater, in a tribal health clinic.  The PICOT question posed 
was: Among primary care providers in a tribal health clinic, does the introduction of an evidence- 
based multi-faceted intervention versus the current practice of no tool, improve the co-
prescription rates of naloxone to chronic opioid patients within a 12-week period?  The project 
was conducted in two Indian Health Service clinics in Southwest Michigan, one rurally located, 
the other within an urban setting.  While each location had a primary, full-time advanced 
practice clinician, both of which were PAs, two additional providers, a full-time staff physician 
and a part-time physician medical director, rotated to all the clinics operated by the tribal 
government.  All providers had been cross-trained to work at each location.  The multi-faceted 
intervention consisted of provider education provided during a one-hour discussion and 
PowerPoint academic detailing session, the utilization of a clinical champion (DNP student 
facilitator), and posters placed strategically throughout the clinic (waiting room, exam rooms and 
bathrooms), which served the dual purpose of visual reminders to the providers and provided 
education to the patients. 
Data collected from a retrospective chart review during a 12-week intervention period 
was compared to the correlating 12-week time period the previous calendar year and manually 
entered into the Statistical Package for the Social Services (SPSS) for statistical analysis.  
Testing was performed to answer the following primary question: 
Question one: What are the naloxone co-prescription rates and are they significantly different 
between the two project periods? 
Statistical analyses also evaluated secondary questions: 
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Question two: Does patient age influence the likelihood of dispensing a naloxone co-
prescription? 
Question three: Does patient gender influence the likelihood of dispensing a naloxone co-
prescription? 
Question four: Does the amount of daily MME influence the likelihood of dispensing a naloxone 
co-prescription? 
Question five: Does the concurrent prescription of benzodiazepines influence the likelihood of 
dispensing a naloxone co-prescription? 
Question six: Does the clinic location influence the likelihood of dispensing a naloxone co-
prescription? 
Question seven: Does the provider discipline (PA or physician) influence the likelihood of 
dispensing a naloxone co-prescription? 
Participants 
Physician one had over 20 years of clinical experience and had been working with the 
tribal clinic for approximately four years.  This part-time physician serves as the medical director 
of the clinics, rotating between sites on a weekly basis.  Physician two had over 25 years of 
clinical experience and worked full time, alternating between the rural and urban clinics.  
Physician two had been employed by the tribe for the past three years, but on a part-time basis 
until the past year.   PA one had nearly 30 years of clinical experience and had been employed 
by the tribal clinic for approximately six years, working from the rural location.  The final 
provider, PA two, was the most recent to join the staff, having approximately three years of 
clinical experience and working for the tribal clinic in the urban location for the past two years. 
Clinic patients were eligible to receive a naloxone co-prescription from the provider 
during the EBP project if they were a federally recognized tribal member, spouse of a tribal 
member, or otherwise eligible to be seen at either clinic location as an employee of the Tribal 
Government.  Additionally, eligible patients were ages 18 and above, non-pregnant, and 
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receiving an opioid prescription (of any MME equivalents) of 30 days or greater during the EBP 
project.   
Consistent with Kotter’s model and the team-based approach, patients were considered 
eligible for inclusion regardless of a medical visit occurring during the 12-week intervention.  
Since the clinics offer services across several healthcare modalities, eligible patients may have 
been physically present at the clinic during the intervention either accessing another service or 
presenting to pick up a physical prescription for the opioid medication.  Therefore, team 
members had opportunities unique to this setting to offer naloxone co-prescriptions outside of a 
traditional medical clinic visit. 
Size and Characteristics 
 Pre-Intervention Group Characteristics.  A retrospective chart audit of patients’ 
medical records was conducted to collect baseline data.  Data was compiled from 48 medical 
records of patients who received a 30-day or greater prescription of opioids in the 12-week 
period dating September 25th, 2016 to December 15th, 2016.  The chart audit consisted of 
patients ranging in ages from 26 to 72 years.  The mean age was 50.0 years (SD = 10.46).  Of 
the group, 33.3% (n = 16) were male and 66.7% (n = 32) were female.  The majority of the 
patients, 56.3% were of ‘other tribal affiliation” (n = 27), members of the tribal affiliation which 
funds the clinics constituted 41.7% (n = 27) of the audited charts; patients in the remainder 
2.1% of audited charts were categorized as “non-tribal affiliation” (n = 1).  During the 12-week 
audit period, 75% (n = 36) of the patients did have a clinic visit occur, while the remainder did 
not.  The majority of eligible patients were patients of the urban location, 58.3% (n = 28); while 
the remaining patients, 41.7% (n = 20) were patients at the rural location.  Prescribing provider 
discipline was equally split among patients with PAs and physicians, each writing 50% (n = 24) 
of the opioid prescriptions in the audit period. The mean daily MME was 24.6 (SD = 18.37) with 
a range of 5 to 95 MME.  Additionally, 8 (16.7%) of the patients received a benzodiazepine 
prescription in addition to their opioid prescription (see Table 4.1). 
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 Intervention Group Characteristics.  Data was collected from a total of 40 patients 
who obtained an opioid prescription of 30 days or greater during the 12-week intervention period 
that occurred between September 25th through December 15th, 2017.  The patients were similar 
in age to the pre-intervention group, ranging from 29 to 70 years old with a mean age of 49.9 
years (SD = 10.44).  The intervention group, however, did have a higher percentage of females, 
72.5% (n = 29) than the previous group.  Accordingly, the percentage of male patients was less 
(27.5%, n = 11).  Membership of the tribe which funds the clinic was 37.5% (n = 15), non-tribal 
affiliated patients accounted for 10% (n = 4) of the opioid prescriptions, and the majority of the 
patients receiving opioids were of other tribal affiliations (52.5%, n = 21).  The overwhelming 
majority of the patients, 37 (92.5%) did have a visit during the intervention time frame, while only 
the remaining three did not (7.5%).  As noted with the pre-intervention group, the urban located 
clinic was the source of the majority of the patients receiving an opioid prescription 65% (n = 
26), while the remaining 35% (n = 14) were patients at the rurally located clinic.  A physician 
was the prescribing provider for 55% (n = 22) of patients receiving an opioid during the 
intervention period, while 45% (n = 18) of the patients were prescribed by the PAs.  Daily MME 
among opioids prescribed ranged from 2.5 to 172.5, with a mean of 24.16 (SD = 30.96).  Only 
22.5% (n = 9) patients in the group received a concurrent benzodiazepine prescription, while the 
remaining 77.5% (n = 31) did not (see Table 4.1). 
Changes in Outcomes 
Statistical Testing and Significance 
 Using SPSS Version 22 for analysis, parametric tests were run to compare the naloxone 
co-prescription rates between the two groups: pre-intervention (N = 48) and intervention (N = 
40).  Statistical significance for all data was established as p < .05.  A chi-square test of 
independence was calculated to analyze the association between the use of a multi-faceted 
intervention and naloxone co-prescription rates.  Secondary variables of interest were 
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calculated within the post-intervention group utilizing chi-square analyses and independent 
samples t testing.  
Findings 
 Primary outcome. 
Question one: What are the naloxone co-prescription rates and are they 
significantly different between the two project periods?  During the pre-intervention group, 
there were no naloxone co-prescriptions distributed (0 of 48 eligible patients) while 10 of the 40 
eligible patients within intervention group (25%; X2 = 13.538, p <.001) had naloxone distributed 
(see Figure 4.1).  Additionally, all 10 of the patients who received the naloxone co-prescription, 
did have a clinic visit occur during the intervention period. A further demographic breakdown of 
those who received naloxone and those who did not is available in Table 4.2. 
Secondary outcomes. 
Secondary descriptive statistics were calculated within the post-intervention group to 
evaluate if further relationships existed.  Parametric and non-parametric tests were utilized as 
appropriate.   None of the secondary variables of interest, except patient gender, were found to 
affect naloxone distribution. 
 Question two: Does patient age influence the likelihood of dispensing a naloxone 
co-prescription?  An independent-samples t test comparing the mean ages of patients which 
received naloxone co-prescriptions against those who did not.  The mean age of people who 
received naloxone (M = 50.5) was not significantly different from the mean age of those who did 
not. (M = 49.7; t = 0.207, p = .837). 
Question three: Does patient gender influence the likelihood of dispensing a 
naloxone co-prescription?  In the intervention group, 11 male patients and 29 female patients 
were eligible to receive a naloxone co-prescription (see Figure 4.2).  However, none of the 
eligible males received one, while 10 (34.4%) of the 29 eligible females did (X2 = 5.057, p = 
.025).  
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Question four: Does the amount of daily MME influence the likelihood of 
dispensing a naloxone co-prescription? Review of the data indicated that there was a wide 
range in the daily MME patients who had been co-prescribed naloxone, ranging from 10 to 
172.5 daily MME.  Patients in the intervention group who did not receive a naloxone co-
prescription had daily MME ranging from 2.5 to 95.  The mean daily MME of the patients who 
received naloxone co-prescriptions (M = 39.68) did not significantly differ from eligible patients 
who were not prescribed naloxone (M = 22.99; t = 1.500, p = .142).    
Question five: Does the concurrent prescription of benzodiazepines influence the 
likelihood of dispensing a naloxone co-prescription?  Within the intervention group, nine of 
the 40 patients (22.5%) had a concurrent benzodiazepine prescription, one of the additional risk 
factors for opioid overdose potential.  Of the 10 patients who received a naloxone co-
prescription, 30% (3 patients) were concurrently receiving a benzodiazepine prescription.  No 
statistically significant relationship was found (X2 = .430, p = .512).   
Question six: Does the clinic location influence the likelihood of dispensing a 
naloxone co-prescription?  Since each of the clinics served a unique population due to the 
contrasting urban and rural populations, naloxone co-prescriptions between locations was also 
evaluated.  The rural clinic serviced 35% (n = 14) of the eligible patients while the urban clinic 
serviced the remaining 65% (n = 26).  As mentioned previously, naloxone co-prescriptions were 
dispensed ten of the total eligible 40 patients.  Of the ten, two (20%) were the rural patients and 
eight (80%) were the urban patients.   Although the urban setting had a 4:1 ratio over the rural 
setting, clinic location did not appear to be a statistically significant factor in naloxone co-
prescription rates (X2 = 1.319, p = .251). 
Question seven: Does the provider discipline (PA or physician) influence the likelihood 
of dispensing a naloxone co-prescription?  Finally, comparisons between disciplines was 
conducted.  While each of the PAs were stationed primarily at one clinic, both the full-time and 
part-time physician rotated among the clinics.  Interestingly, the physicians prescribed the 
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majority, 70% (n = 7) of the naloxone co-prescriptions, while the PAs prescribed 30% (n = 3).  
However, the physicians also saw a slight majority, 55% (n = 22), of the eligible patients in the 
intervention phase.  Provider discipline did not appear to be a factor in naloxone co-prescription 
rates (X2 = 1.212, p = .271).  A further breakdown of provider dispensing patterns in located is 
Table 4.3.   
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Table 4.1 
Group Characteristics 
 Pre-Intervention Intervention 
Gender Frequency Percentage Frequency Percentage 
Male 16 33.3% 11 27.5% 
Female 32 66.7% 29 72.5% 
Tribal Affiliation     
Funding Tribe 20 41.7% 15 37.5% 
Other Tribe 27 56.3% 21 52.5% 
Non-Tribal 1 2.1% 4 10.0% 
Clinic Location     
Rural 20 41.7% 14 35.0% 
Urban 28 58.3% 26 65.0% 
Clinic Visit During Audit Period    
Yes 36 75.0% 37 92.5% 
No 12 25.0% 3   7.5% 
Concurrent Benzodiazepine Prescription   
Yes 8 16.7% 9 22.5% 
No 40 83.3% 31 77.5% 
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Table 4.2 
Intervention Group Characteristics 
 Naloxone No Naloxone 
Gender Frequency Percentage Frequency Percentage 
Male 0 0% 11 36.7% 
Female 10 100% 19 63.3% 
Tribal Affiliation     
Funding Tribe 1 10% 14 46.7% 
Other Tribe 9 90% 12 40% 
Non-Tribal 0 0% 4 13.3% 
Clinic Location     
Rural 2 20% 12 40% 
Urban 8 80% 18 60% 
Clinic Visit During Audit Period    
Yes 10 100% 27 90% 
No 0 0% 3 10% 
Concurrent Benzodiazepine Prescription   
Yes 3 30% 16 20% 
No 7 70% 24 80% 
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Table 4.3 
Naloxone Co-Prescriptions Dispensed by Provider Type 
 Physician 1 Physician 2 PA 1 PA 2 
Naloxone Prescribed - Yes 1 6 2 1 
Naloxone Prescribed - No 1 14 11 4 
Clinic Location (Rural/Urban) 0/2 1/19 13/0 0/5 
Total Eligible Patients 2 20 13 5 
Adoption/Co-Prescribing % Per 
Provider 
50% 30% 18.18% 20% 
Adoption/Co-Prescribing % 
Within the Organization 
 5% 50% 32.5% 12.5% 
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Figure 4.1 
 
Improvement in Naloxone Co-Prescription Rates 
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Figure 4.2 
Naloxone Distribution by Gender 
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CHAPTER 5 
DISCUSSION 
This EBP project was designed to answer the PICOT question: “Among primary care 
providers in a tribal health clinic, does the introduction of an evidence-based multi-faceted 
intervention versus the current practice of no tool, improve the co-prescription rates of naloxone 
to chronic opioid patients within a 12-week period?”  This project, which was implemented at 
two clinics located in the Midwest within an Indian Health Services Health Department, sought 
to determine if a multi-faceted intervention, which included an academic detailing session, the 
use of a clinical champion and visual reminders, influenced the behavior of providers to increase 
naloxone co-prescription rates.  An explanation of project findings, along with examination of 
key factors that contributed to success and project limitations, will be discussed in this chapter.  
Additionally, evaluation of theoretical and EBP framework utilized to guide this project and 
implications for future projects of this nature will also be detailed. 
Explanation of Findings 
Although the naloxone distribution policy from which this project was initially conceived, 
was part a larger organizational policy, logistical implementation and acceptance was left up to 
the individual departments of the organization.  The evaluation plan for this EBP project was 
directed to answer the primary outcome question, but also was intentionally designed to 
evaluate secondary outcomes in an effort to guide future naloxone co-prescription practices. 
Question one: What are the naloxone co-prescription rates and are they significantly 
different between the two project periods?  As the primary outcome for this project, the majority 
of focus was placed on this particular query.  Initially, zero naloxone prescriptions had been 
distributed in the pre-intervention stage (n = 0, N = 48).  The pre-intervention period data was 
procured via a retrospective chart audit of eligible patients who obtained an opioid prescription 
of 30 days or greater during the time period of September 25th, 2016 to December 15th, 2016.  
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This data was then manually reviewed to ensure accuracy and quantified using an audit sheet 
developed by the DNP student facilitator. The audit processes were repeated for the 12-week 
period that followed the prescribing providers’ AD session and distribution of educational 
materials by the clinical champion (September 25th to December 15th, 2017).  Initially, the timing 
of the project was scheduled to coincide with the purchase and delivery of naloxone stock and 
availability of providers to attend the AD session; however, a delay in the naloxone stock 
delivery, caused the product to be unavailable for physical distribution within the clinic setting for 
the first 10 days of the project intervention period. Thus, providers initially had to write a 
prescription to be filled by the patient elsewhere.  Of the 40 possible eligible patients receiving 
an opioid prescription of 30 days or greater during the intervention period, 25% (n = 10) were 
given a naloxone prescription, a statistically significant increase (X2 = 13.538, p <.001). The 
increased percentage of co-prescriptions written for eligible patients was congruent with the 
supportive evidence reviewed for this EBP project (Behar et al., 2017; Bounthavong et al., 2017; 
Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017). 
Additional secondary outcomes were evaluated based solely on data from the 
implementation period since no naloxone co-prescriptions had been given pre-implementation.  
To evaluate if any further relationships existed, additional parametric and non-parametric testing 
was completed to determine statistical significance. 
Question two: Does patient age influence the likelihood of dispensing a naloxone co-
prescription?  Previous literature indicated that providers were more likely to prescribe naloxone 
to patients who were older (Behar et al., 2016).  However, within this EBP project, the age of 
those who received naloxone (M = 50.5) was similar to those who did not (M = 49.7); therefore, 
a statistical relationship relating to age was not established (t = 0.207, p = .837). 
Question three: Does patient gender influence the likelihood of dispensing a naloxone 
co-prescription?  While male patients represented 27.5% of those eligible for the co-
prescription, none received the naloxone.  Females accounted for the remaining 72.5% of the 
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population and were the recipients of 100% of the naloxone distributed during the project.  
Although none of the supportive evidence reviewed for this project indicated gender bias in co-
prescribing, the difference in co-prescribing among gender within this project did achieve 
statistical significance (X2 = 5.057, p = .025).  
Question four: Does the amount of daily MME influence the likelihood of dispensing a 
naloxone co-prescription?  Behar (2016) discussed that prescribing providers were to utilize 
naloxone co-prescriptions among either subgroup of patients prescribed high (> 20 MME) or low 
dose (< 20 MME).  Among the patients seen during the intervention period, there was a wide 
range in the daily MME amount (2.5 to 172.5, M = 24.16, SD = 30.96).  Contrasting Behar’s 
findings, those that received naloxone, did have a higher MME amount (M = 39.68) than those 
who did not (M = 22.99), the difference among these groups could be attributed to the small 
population size and the inclusion of one outlier who had a daily MME of 172.5 (one of the 
naloxone recipients).  This postulation was further supported when statistical significance was 
not established regarding prescribing patterns related to daily MME (t = 1.500, p = .142). 
Question five: Does the concurrent prescription of benzodiazepines influence the 
likelihood of dispensing a naloxone co-prescription?  Guidelines indicate that concurrent use of 
benzodiazepines are a risk factor for increased opioid overdose potential, and this was an issue 
that was discussed during the AD session conducted by the clinical champion (Alexander et al., 
2015; CDC, 2016a; Duvivier et al., 2017; USDHHS, 2016).  When the providers were provided 
their individual list of patients currently receiving opioid prescriptions, concurrent 
benzodiazepine prescriptions included.  Although 30% (n = 3) of the 10 patients receiving a 
naloxone co-prescription were found to be also on a benzodiazepine prescription, overall 22.5% 
(n = 9) of those seen during the implementation period (N = 40) were concurrently receiving a 
benzodiazepine.  This did not indicate statistical significance in regard to naloxone co-
prescribing practices (X2 = .430, p = .512).  
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Question six: Does the clinic location influence the likelihood of dispensing a naloxone 
co-prescription?  Early community distribution programs for naloxone have focused on urban 
populations, and current literature appears to maintain much of the same focus (Behar et al., 
2016; Behar et al., 2017; Binswanger et al., 2015; Bounthavong et al., 2017; Coffin et al., 2016; 
Delaney et al., 2016; Devries et al., 2017; Mueller et al., 2015; Wilson et al., 2017; Winograd et 
al., 2017).  However, the CDC (2016b & 2016c) has indicated that both rural and urban 
populations are affected by opioid overdose and are in need of intervention.  Naloxone co-
prescriptions were dispensed to 10 of the total eligible 40 patients.  Of those 10, two (20%) were 
rural patients and eight (80%) were urban patients. While the urban setting in this EBP project 
dispensed naloxone prescriptions at a 4:1 ratio over the rural setting, this difference was not 
statistically significant (X2 = 1.319, p = .251). 
Question seven: Does the provider discipline (PA or physician) influence the likelihood of 
dispensing a naloxone co-prescription?  While the DNP student facilitator was the EBP project 
leader and clinical champion, she was also the only nurse practitioner within the practice, 
stationed at a third location of the organization, which due to its focus on acute care visits, did 
not typically see patients who would meet project inclusion criteria.  Therefore, the DNP student 
facilitator postulated that the other advanced practice clinicians (PAs) may be more open to 
adoption of the naloxone co-prescribing intervention since they had an educational attainment 
level similar to the clinical champion.  It was also postulated that since both of the PAs were 
stationed full time in a single clinic, they would take more ownership of eligible patients and thus 
have higher naloxone co-prescribing adoption levels when compared with the full time MD and 
part-time MD who rotated between each of the clinics.  However, during the intervention period, 
physicians saw 55% of the eligible patients (n = 22, N = 40) and prescribed 70% of the naloxone 
(n = 7, N = 10).  Ultimately, this correlation also did not achieve statistical significance (X2 = 
1.212, p = .271).   
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Evaluation of Applicability of Theoretical and EBP Frameworks 
 To guide this project systematically, both a theoretical framework (Kotter’s Model of 
Change) and an EBP framework (the Iowa Model of Evidence-Based Practice to Promote 
Quality Care) were utilized.  The applicability of both will be discussed further below. 
Theoretical Framework 
 The Model of Change, developed by John Kotter has provided a linear approach to 
behavioral change in an organization (Melnyk & Fineout-Overholt, 2015).  While the project 
facility was smaller in size than others in similar projects (Behar et al., 2016; Behar et al., 2017; 
Bounthavong et al., 2017; Coffin et al., 2016; Delaney et al., 2016; Devries et al., 2017; Oliva et 
al., 2017; Wilson et al., 2017), numerous organizational obstacles still needed to be addressed 
to ensure project success; thus, Kotter’s model was well suited to this EBP project.  
 Kotter’s first step, establishing a sense of urgency, was instrumental for obtaining the 
support and cooperation of those involved with the change process.  Much of this step was 
initiated prior to the development of this EBP project.  Due to a heightened awareness created 
by national media coverage, the recent tribal health survey, and the ability to attend various 
seminars and webinars by both management and clinical staff, support for the project was 
garnered.  Organizational leaders were aware of the opioid epidemic and thus had drafted a 
policy for naloxone distribution, but clinically this had not been implemented due to lack of 
process and procedures.  The top-down approach of recognition and acknowledgement of the 
clinical problem was the catalyst for this project. 
 The second step was to create a powerful guiding coalition.  With the support of upper 
level organizational leadership and health department management, a clinical team was 
assembled to determine how to best implement the naloxone distribution policy and ensure safe 
opioid prescribing practices.  While initially this team included the prescribing providers and RN 
clinical manager, it was later expanded to include members of behavioral health and other 
clinical support staff.  Working on projects in a team-based format was familiar to the invested 
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parties and was further supported by utilizing Kotter’s model.  As the timing of these initial first 
steps coincided with the DNP student facilitator’s educational plan for an EBP project, it became 
an obvious and unanimous decision for the DNP student facilitator to lead the group and direct 
the project.  Further support of the project was realized when management, recognizing the 
sense of urgency, (a) allowed team members to block schedules to attend meetings, (b) 
supported the DNP student facilitator’s use of available work resources (i.e., computer, internet, 
printer, and copier), and (c) permitted the DNP student facilitator to work on the project during 
periods of decreased patient down time. 
 Consistent with Kotter’s third step of developing a vision, the assembled clinical team 
determined that they would like to pilot an evidenced-based method to distribute naloxone to 
current clinic patients as another positive step in their efforts to enhance safe opioid prescribing 
practices.  As organizational leadership had already developed and approved a general policy 
that supported naloxone distribution to anyone who accessed clinic services, the team needed 
to further refine that vision and develop a strategy which would garner widespread support.  
Thus, after review of literature and synthesis of available evidence, it was envisioned that all 
clinic patients who received opioid prescriptions of 30 days or greater would be co-prescribed 
naloxone.   
 While the prescribing providers and RN clinical manager had been supportive of the 
project from inception, it was recognized that discussion of opioid overdose prevention 
strategies could be an uncomfortable topic for others; therefore, it was imperative to develop a 
clear strategy to complete Kotter’s fourth step: communicating the vision.  Team members 
sought to include ways to decrease barriers and misconceptions regarding the distribution of 
naloxone for potential administration by lay persons.  To address the issue among clinic staff, 
some with medical knowledge and some without, a brief naloxone detailing session was 
provided by the DNP student facilitator during a health staff meeting.  The session afforded an 
opportunity to communicate the vision of the project and aided in eliminating preconceived 
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negative ideas or thoughts regarding naloxone.  Questions were welcomed and addressed in 
the group setting and a further opportunity to address any other questions or concerns in private 
was also provided.  This academic detailing was duplicated at a more in-depth session for 
behavioral health staff who, coincidentally, began distributing naloxone to their own at-risk 
clients during the same time period.  To communicate the vision of naloxone distribution and 
eliminate potential misconceptions of naloxone, further communication to patients and clients 
was conducted via written and pictorial methods, as well as one-on-one discussions.  To 
achieve this, a brief article, written in layman’s terminology, was authored by the DNP student 
facilitator, and included within the quarterly health publication that was distributed to all patients 
and clients who accessed the health department (Appendix J).  Additionally, 8.5” x 11” posters 
from prescribetoprevent.org (Appendix E) were obtained, printed, and placed in the waiting 
areas, the backs of restroom doors, and in examination rooms. 
 Kotter’s fifth step has focused on empowering others to act on the vision.  To accomplish 
this, the team decided that including clinical staff in the AD session and giving them access to 
the naloxone stock would be beneficial.  While the intended outcome of this EBP project was to 
improve naloxone co-prescribing rates among those receiving opioid prescriptions of 30 days or 
greater, the ultimate goal was increase naloxone acceptance and availability among the tribal 
community.  It was felt that giving other staff members, clinical or not, knowledge of the 
processes so that they were able to inform others would work towards these larger goals while 
supporting the prescribing providers’ more immediate and measurable goals of this project. 
 The sixth step in Kotter’s model, planning for and creating short-term wins, was achieved 
in a number of ways.  Throughout the project, administrative support was readily given, thus 
facilitating the staff’s acceptance of the change process.  Allowing staff and the DNP student 
facilitator time to work on the project as a team propelled this intervention forward.  The major 
win, however, was when organizational leadership approved a direct purchase agreement and 
funding for the naloxone to be physically stocked within the clinic.  While this additional support 
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was not initially anticipated, the DNP student facilitator became aware of this initiative during the 
planning stages and incorporated the distribution of stocked naloxone into the implementation 
phase.  The acquisition of physical naloxone stock eliminated multiple barriers; patients would 
be able to receive naloxone without worry of cost, availability, or acquisition.  For staff, this early 
win was helpful in the anchoring change process, as it created a pathway that would ease and 
simplify the procedure of naloxone distribution.  Further short-term wins were celebrated by the 
occasional delivery of snacks brought by the DNP student facilitator and left in the break areas 
for all staff to enjoy, written with a visual message of “Nalox (save some) one: Thanks for all you 
do!”  This reinforcing strategy also created an opportunity for staff not directly involved with the 
project to have conversations regarding naloxone, further contributing to sustained 
organizational change and acceptance.  Other short-term wins that were directed more 
specifically towards the prescribing providers were regular updates at monthly provider 
meetings regarding the progress of distribution, such as when the first naloxone had been 
dispensed.  As was supported in the literature, (Behar et al., 2016; Coffin et al., 2016), a 
planned, formalized email was sent at the midway point of the implementation to the prescribing 
providers which communicated distribution progress to that point thanking them for their 
participation, celebrating the progress to date and providing a reminder to continue with 
naloxone co-prescribing practices. 
 Although Kotter’s model was designed to be linear in nature, the seventh step 
(consolidating achievements and producing more change) was recognized both during the 
implementation stage and following implementation as data were evaluated. While during the 
sixth stage, progress was being communicated for short term wins, this was simultaneously 
contributing to the formalized step in the model.  At the conclusion of the implementation stage, 
all data, results and achievements were translated into a narrative format which describes the 
overall effect of the practice change.  Furthermore, the results of the EBP project contribute to 
anchoring practice change by recognition of future barriers and additional adaptations needed.  
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The changes were further anchored during the process of transitioning to a new EHR system, 
when the team constructed built in templates for ease of documentation.  Additionally, realizing 
the distribution process was successful and being utilized by several departments from a single 
naloxone stock, funds for the 2018 fiscal year were procured to continue to provide the supply.  
Finally, while outside the time constraints of this intervention period, it has been noted during 
informal reviews of current naloxone distribution logs that other patients with a documented 
chronic opioid medication, have since received naloxone.  Most notable is that several of these 
patients are male.  This is indicative that naloxone co-prescribing practices are continuing to be 
adopted by providers and accepted by patients. 
 The eighth and final step in Kotter’s Change Model is institutionalizing new approaches.  
Again, while linear in design, this final step was considered throughout the project in an effort to 
not just change naloxone co-prescribing practices for chronic opioid patients, but to change the 
naloxone perception and availability for all who utilize the clinic.  The team recognized that this 
process change was a new approach to safe opioid prescribing and may be uncomfortable for 
staff and patients to discuss and accept.  Through this EBP project, patients and staff became 
more accustomed to naloxone distribution and created a new culture of acceptance and 
standard of practice, thus creating a sustainable and viable practice change.  To continue 
sustainability and anchor organizational change, further efforts have been made to ensure 
naloxone stock continues to be accessible to those who utilize it and the DNP student facilitator 
continues to act as clinical champion.  Additional measures to ease documentation and alert 
providers of eligible patients are being built into the new EHR, which will further anchor co-
prescribing practices.  Recognizing that measures to combat the opioid epidemic, whether from 
prescribed medications or illicit substances, are rapidly changing, the health department director 
and clinical manager continue to support ongoing efforts to stay abreast of the latest trends.   
Recently, they have approached the DNP student facilitator, requesting that she attend the May 
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2018 National Tribal Public Health Summit and Tribal Health Opioid Consultation, as a 
representative of the Clinic X Tribe.  
EBP Framework 
 EBP is model of care driven by evidence-based research, clinical expertise and patient 
preference (Schmidt & Brown, 2015).  Using these elements, the utilization of EBP improves the 
quality and outcomes of patient care.  The use of EBP models assists in translating evidence 
into clinical practice and provides a systematic approach to navigating complex healthcare 
systems and disciplines.   
The Iowa Model was chosen for this project as it provides stepwise, team-based 
approach to initiating change. The Iowa Model includes (a) identifying a problem-focused or 
knowledge-focused trigger, (b) determining if the problem is identified as a priority for the 
organization, (c) assembling a team, (d) reviewing and synthesizing the available literature, and 
(e) conducting a pilot change (Titler et al., 2001).   
 Several of the steps with the Iowa Model correlated with Kotter’s 8-Step Process of 
Leading Change; thus complementing each other in theory and framework. The Iowa Model 
was a good fit because it provided the necessary guidance to initiate the change process. The 
five steps of the process were easy to follow and provided the doctoral student guidance and 
support for initiating change in a practice that was not engrained with EBP.   As the organization 
had already made clear that the issue of naloxone distribution was a priority, the first step, 
identifying a problem-focused trigger, was easily recognized.  Thus, the creation of the team, led 
by the doctoral student, was undertaken, and a review of the literature embarked upon.  The 
Iowa Model directed the team and the DNP student facilitator (in her role of team leader) to 
assemble and evaluate evidence that was used to guide implementation of the EBP project.   
 Upon determining there was sufficient evidence available to proceed with a pilot practice 
change, the Iowa Model further guided the DNP student facilitator and team to collect baseline 
data, determine outcomes and begin implementation.  The pilot change was determined to be 
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successful based on the increase in naloxone co-prescriptions distributed during the 
intervention period.  Additional review to further improve the EBP practice change has been 
discussed in efforts to improve on the current process, with a new outcome objective of 
increasing the naloxone co-prescription rate to 75% of all eligible chronic opioid users.  The 
team initially formed for this project will remain in place and be utilized to translate other EBP 
projects into clinical practice changes.   
Strengths and Limitations of the EBP Project 
Strengths 
 This EBP project had numerous strengths.  The one considered to have the most 
impactful effect on the project was the collaboration and cooperation of the leadership and 
prescribing providers.  The support and desire of the leadership to see this project facilitated 
and directed was instrumental in the undertaking and success.  The utilization of synthesized 
literature to implement evidence-based practice changes was a strength to garner support from 
leadership sources.  In this project, the health department director and organizational leadership 
did not have a clinical background; their area of expertise was business management.  Knowing 
this, the DNP student facilitator utilized data in terms of significance, costs, and potential long-
term savings to further anchor support for the long-term sustainability of this practice change. 
Additionally, the collaboration of the prescribing providers, who themselves, while resistant to 
changes as most individuals are, recognized that this was an issue which needed to be 
addressed.  The attention and time devoted by all vested parties proved to be a key 
consideration, further aligning with Kotter’s Model of Change and the Iowa Model directive to 
determine if an issue is a priority to the organization. 
 A second strength to this project was the procurement of physical stock and availability 
of naloxone.  While this was not planned for initially, it was helpful and eliminated barriers 
previously noted in similar projects (Behar et al., 2017; Behar et al., 2016; Coffin et al., 2016; 
Delaney et al., 2016).  It also answered one of the questions initially posed by providers, who 
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queried, “even if we write the prescriptions, how do we know they (patients) are filling them?”    
The procurement of this stock and initiation of this project also provided an avenue for other 
disciplines within the clinic to begin discussions with clients and facilitated the development of a 
procedure that enabled staff to dispense kits to those individuals who were felt to benefit from 
the receipt of naloxone, whether for themselves or an at-risk family member. 
 Additionally, this project provided a basis on which to open communication lines 
between organizational leadership, the health department, tribal police department and the tribal 
affiliated casino security, and emergency medical technician (EMT) staff.  Discussion and 
implementation of this project, designed to focus on naloxone co-prescribing, sparked further 
undertakings to increase naloxone awareness, increase community distribution, and decrease 
the negative stigma often associated with naloxone utilization.  Through these communications, 
the tribal council of the organization has approved future funding for naloxone purchasing, the 
tribal police have secured their own stock, and the casino EMTs have had naloxone training and 
carry it in their medical bags.  The tribal police department has also agreed to the installation of 
a secured “Red Med Box” in which unused medications, including opioids, can be safely 
disposed.  This box had previously sat in the basement of the health department unused and 
essentially forgotten, until discussion directly stemming from this project occurred.  
 Finally, the use of the DNP student facilitator in the role of the clinical champion was 
viewed as a strength.  While the facilitator was completing the final portion of her doctoral 
studies, she was also a practicing NP employed within the organization.  This first-hand 
knowledge was beneficial to the implementation process and navigation of the organizational 
structure unique to tribal entities.  The utilization of a prescribing provider colleague in this role 
allowed the AD sessions and subsequent contacts with the providers to be tailored to meet the 
individual personalities and needs, thus creating further acceptance of a practice change. Time 
devoted to leading the change, armed with current knowledge of standard practice within the 
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organization, the barriers that may be encountered as well as the expertise and focus for 
completion, proved to be instrumental in the successful implementation of this EBP project. 
Limitations 
 While the project had multiple strengths, it certainly was not without limitations.  The 
major obstacle in the EBP project was the sample size.  Having only four prescribing providers 
and a small pool of eligible patients (pre-intervention: N = 48, intervention: N = 40) from which to 
conduct analyses made it difficult to determine if these results would be replicable on a larger 
scale, although they were similar to 25% adoption rates reported in the literature (Devries et al., 
2017), and if the percentage change would be statistically significant if the larger population size 
provided adequate power to determine the intervention effect.  While the clinical champion was 
a nurse practitioner, the providers in the intervention only represented two of the three major 
disciplines often seen in primary care, which limits the ability to confidently translate the results 
of this EBP project across all education backgrounds. Devries et al. (2017) noted that 
physicians (85.3%) were found to be more likely to prescribe naloxone than NPs (9.8%) and 
PAs (3.7%), a finding that was replicated similarly in this project (physician prescribing 
accounted for 70% of the naloxone co-prescriptions).  Consideration of different academic 
backgrounds and/or multiple clinical champions may be indicated for future projects of this 
design. 
 Another limitation to this project was being conducted in an organization that while well-
versed in grants, QI projects and data collection, was not familiar with formal EBP processes.  
Although IRB approval was obtained from the university IRB, the project facility did not have a 
formal IRB in place. This was an organization that typically had dissemination through tribal or 
governmental channels and was not familiar with the IRB processes which were deemed 
necessary by the university to ensure protection of subjects for dissemination of findings.  When 
the DNP project facilitator approached management and the health department director early in 
the process to review the planned intervention and explain the needed approvals, management 
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determined that the university IRB approval would be sufficient.  A week prior to the planned 
intervention start, the health director of the organization began to reconsider whether the 
university IRB would be adequate or if a further review process was indicated.  The university 
IRB packet and approval were given to the health director for review; and, the director 
determined that the processes included within the university IRB application were thorough 
enough to meet the needs of the tribal organization and permission was obtained to proceed 
with the proposed intervention.  While ultimately, no delay in the proposed start date occurred, 
the timing of the additional review by organizational leadership did result in additional concerns 
about being able to carry out the academic detailing sessions as scheduled and determining 
whether the project would be conducted at all. 
An issue which did delay full implementation status, but ultimately did not appear to 
hinder the project outcomes was the availability of the physical naloxone stock.  The project was 
carefully timed to encompass every three month visit recommendations from the CDC (2016a), 
while avoiding the decreased patient volume due to multiple closures related to the approaching 
holiday season.  As mentioned previously, the availability of the naloxone stock was not part of 
the original planned intervention.  However, this beneficial procurement was approved and 
therefore, incorporated into project.  Due to the time constraints of implementation start dates 
and availability of the providers, it was deemed prudent to proceed with the scheduled AD 
sessions even though the naloxone stock had not arrived at the project facility.  The prescribing 
providers were instructed to write for a prescription of naloxone, which the patient could then fill 
at an off-site pharmacy of their choosing during the interim.  Stock arrived ten days after the AD 
sessions and was distributed the following day to both project sites by the DNP student 
facilitator.  Although the DNP student facilitator recognizes that not all clinic facilities attempting 
to replicate this EBP project, will be able to supply naloxone directly to the patients, presumably 
due to the cost factor, it is noted that no naloxone prescriptions were written when the naloxone 
stock was unavailable.   
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 Another confounding factor that occurred during this project period was the simultaneous 
implementation of naloxone distribution by the behavioral health staff, potentially providing 
naloxone to mutual patients of the clinic and thus, removing them from data capture.  Although 
the intention of the project had been made clear to all management staff early in the process, 
limited opportunities for communication specifically with the behavioral health manager hindered 
collaboration between the departments.  This resulted in a separate, parallel intervention 
occurring concurrently with the health clinic intervention.  While the DNP student facilitator was 
able to provide a brief AD session to the behavioral health clinicians, it was not specifically 
tailored to their educational background and was limited regarding time allotment.  Additionally, 
all naloxone was distributed from stock maintained in the clinic via locked access.  Although 
tracking forms and a process was implemented to track what patients had received naloxone, 
this was not seen to fruition with the behavioral health staff.  This resulted in a potential loss of 
data capture if behavioral health distributed to a shared patient without full documentation on 
the tracking logs. 
 The project facility has faced many challenges with their current EHR and although the 
clinical champion worked with the CAC on several initiatives to ease documentation and 
educational components regarding naloxone co-prescriptions, this was done with the awareness 
that the project facility was changing to a new EHR in the coming fiscal year.  While specific 
education was given during the provider AD session regarding the process for documentation, it 
was found that only one of the naloxone distributions was completed in the EHR and the rest 
were tracked solely via the paper distribution log maintained with the naloxone stock.  It remains 
unclear if the resistance to documentation in the EHR lies with the cumbersome way it must 
occur, provider resistance to process change or whether the effort to do so was lacking knowing 
that a new documentation system would be implemented in the near future. 
Although initially planned to occur more frequently, the clinical champion was limited in 
face to face contact.  Although the providers were accustomed to practicing in separate clinics, 
NALOXONE CO-PRESCRIBING  82 
 
there had previously been opportunities for at least monthly in person contact and further video 
conferencing contacts.  Due to a change in the way monthly health staff meetings were 
conducted and the inability to video conference related to equipment issues, the clinical 
champion’s ability to have in-person contact was limited.  Phone and email contacts were 
increased to counteract this issue, however the effect, whether positive or negative, this may 
have had on the overall intervention cannot be determined. 
Additional limitations that are notable include the rate of patient acceptance.  While this 
project focused on provider adherence to co-prescribing practices, there was no method 
established to determine naloxone acceptance by the patient.  Further, there was no formal 
tracking method to determine if any of the 40 eligible patients in the project had already received 
naloxone from other sources such as community distribution programs.  Finally, although the 
12-week time frame was chosen to mimic CDC (2016a) recommendations of a re-evaluation 
visit, it was also fashioned in that manner to meet the time constraints of the DNP student 
facilitators academic schedule.  Therefore, it is quite feasible that a longer time frame would 
provide increased access to the 40 eligible patients receiving opioids (30 days or greater) and 
result in higher naloxone co-prescribing rates. 
Implications for the Future 
Practice 
 In response to increasing prevalence and focus on the opioid epidemic, several national 
agencies (i.e., the CDC, USDHHS, VHA and IHS) have published guidelines focused on 
promoting safe opioid prescribing.  Each of these respective guidelines have identified naloxone 
co-prescribing as measure to ensure safe prescribing practices, yet the authoring groups have 
given little direction on how to accomplish this task.   
 As clinicians continue to incorporate practice changes to address evolving opioid issues, 
this EBP project demonstrates that advanced practice nurses are well situated to search, 
evaluate, and appraise rapidly evolving research and develop a systematic approach to 
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translate current evidence into daily practice.  This project further represents that even when 
acting as the lone advanced practice nurse among a multi-disciplinary practice setting, doctoral 
prepared nurses are well-positioned to champion the implementation of evidence-based 
practice changes.  This project can easily be replicated to other tribal health facilities and 
primary care settings. 
Theory 
 Change is difficult for many individuals and facilities to embrace.  Therefore, a 
systematic approach that provides a roadmap to incorporate current evidence and guidance for 
overcoming obstacles that may be encountered along the way is crucial when implementing 
changes to parties that may be resistant to doing so.  Kotter’s Change Model and the Iowa 
Model both provided the necessary framework for this project to proceed successfully.  Both this 
theoretical and EBP framework will continue to be beneficial as the DNP project facilitator 
disseminates the results of this project, thus anchoring change in practice and lending support 
to future use of these models when implementing additional EBP practice changes. 
Research 
 Future research should include larger sample sizes and multiple clinical facilities to 
determine generalization of findings across various settings.  Additionally, this EBP project was 
conducted over a 12-week implementation time frame and further longitudinal studies are 
needed to determine if knowledge garnered from the AD session is sustained or if additional 
follow up AD sessions are indicated.  Further, the clinical champion in this project was not 
available to make face-to-face contact on a frequent basis, therefore additional studies should 
evaluate the effectiveness of an off-site versus physically on-site champion and its subsequent 
effect on naloxone co-prescribing rates.   
 While this project facility was able to distribute naloxone at no cost to the patient, this 
may be cost prohibitive to other facilities and therefore, not replicable.  Additional studies should 
be conducted to determine what role, if any, the immediate access plays on provider adoption 
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and patient acceptance rates.  Finally, this project unfortunately was not designed to evaluate 
patient acceptance rates if naloxone was offered.  Thus, future research and QI projects should 
be designed to evaluate those patients who decline naloxone co-prescribing, the barriers for 
acceptance and methodology to decrease those barriers as well as tracking patients who accept 
the prescription and whether or not they ultimately obtain the naloxone. 
Education 
 Although patient education was not a targeted objective of this EBP project, it did occur 
as an unmeasured component through printed materials and provider – patient discussion.  The 
AD sessions developed and tailored for the individual prescribing providers were adapted 
several times to target additional staff members, who may or may not possess clinical 
terminology within their positions.   Hence, the DNP facilitator was well situated to morph 
between clinical language and lay terminology to meet the needs of the intended audience. 
 Additionally, this project further opened communication lines for future education and 
naloxone distribution, potentially to individuals who did not meet inclusion criteria of this project.  
While the prescribing providers, who were the target of this intervention, were supportive and 
receptive to naloxone discussions, it became apparent that not all staff members possessed the 
same level of comfort and at times were visibly uncomfortable when the conversation was 
broached.  Future educational efforts should incorporate increased awareness of the 
participants’ comfort level regarding naloxone and its use in opioid overdose prevention in order 
to best facilitate receptiveness. 
Conclusion 
 This EBP project answered the query posed by the initial PICOT question: Among 
primary care providers in a tribal health clinic, does the introduction of an evidence- based multi-
faceted intervention versus the current practice of no tool, improve the co-prescription rates of 
naloxone to chronic opioid patients within a 12- week period?  The answer was a resounding 
yes.  The project further demonstrated that doctoral prepared advanced practice nurses are well 
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situated and adequately educated to act as change agents by the ability to develop, implement 
and evaluate clinical practice changes.   This a crucial component for improving quality of care 
and patient outcomes through the incorporation of evidence-based practices.  Additionally, this 
project demonstrated that DNP led practice changes can have a positive, unintentional ripple 
effect towards larger collaborative organizational changes. 
Safe opioid prescribing, and naloxone co-prescribing are a rapidly increasing healthcare 
concern which affects people of all genders, ethnicities, ages, geographic locations and 
socioeconomical status.  Even as this EBP project associated with the DNP student facilitator 
coursework comes to a close, the CDC (2018) is releasing new, alarming statistics that the 
Midwestern region saw opioid overdose rates increase 70% from July 2016 to September 2017, 
the point at which this EBP project intervention began.  Experts continue to call for coordinated 
efforts among providers to judiciously prescribe opioids and increase naloxone distribution 
(CDC, 2018).  While this EBP project included small numbers of patients, the findings did 
indicate a viable and effective evidenced-based intervention for primary care providers to 
contribute to safe opioid prescribing and OEND efforts.  Failure to incorporate evidenced-based 
practice into efforts to squelch the ever-shifting horizon of the opioid epidemic could result in 
devastating consequences to those directly affected and their loved ones left behind.   
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APPENDIX A 
CHART AUDIT 
PERIOD: PRE  POST 
MRN#        
 
GENDER    Male  Female 
 
AGE:       
  
TRIBAL AFFILIATION: 
XXX TRIBAL  OTHER TRIBAL  SEC. 813 
 
NALOXONE DISPENSED?  Yes  No 
 
DOCUMENTED IN EHR?  Yes No   N/A 
 
CLINIC HOME:   XX   XX 
 
PROVIDER:   XXX   XXX  XXX  
XXX   XXX  XXX 
 
Qualifying Med?       
 
Daily MME?        
 
Concurrent Benzo Rx?    Yes  No 
 
Clinic Visit During Audit Period? Yes  No 
 
Primary Dx?           
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APPENDIX B 
Slide 1 
Increasing Naloxone Co-Prescription Rates 
Among Primary Care Providers: A Multifaceted-
Approach
Jolane S. Conklin
“I have neither given or received, nor have I tolerated others use of unauthorized aid.”
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 2 
PICOT
(P)Among primary care providers in a tribal 
health clinic, 
(I) does the introduction of a multi-faceted 
intervention
(C) versus the current practice of no tool 
(O) improve the co-prescription rates of 
naloxone to chronic opioid patients 
(T) in a 3-month period? 
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 3 
Literature Search Process
DATABASE SEARCH TERMS LIMITERS ARTICLES 
YIELDED
DUPLICATES ABSTRACTS 
RIVEWED
ARTICLES 
USED
CINAHL naloxone AND prescri* 
AND opioid* OR opiate* 
AND primary OR pharm*
2015-2017, 
English, 
Peer-
Reviewed
30 0 11 2
PsychINFO naloxone AND prescri* 
AND opioid* OR opiate* 
AND primary OR pharm*
2015-2017, 
English, 
Peer-
Reviewed
43 9 11 0
Joanna Briggs 
Institute
naloxone 2015-2017 4 0 0 0
Cochrane naloxone AND prescri* 
AND opioid* OR opiate* 
AND primary OR pharm*
2015-2017, 
Cochrane 
Reviews
5 0 0 0
MEDLINE (via 
EBSCO)
naloxone AND prescri* 
AND opioid* OR opiate* 
AND primary OR pharm*
2015-2017, 
English, 
Peer-
Reviewed
102 47 12 6
ProQuest naloxone AND prescri* 
AND opioid* OR opiate* 
AND primary OR pharm*
“naloxone” in abstract
2015-2017, 
English, 
Peer-
Reviewed
39 9 2 0
PsychArticles naloxone AND prescri* 
AND opioid* OR opiate* 
AND primary OR pharm*
2015-2017, 
English, 
Peer-
Reviewed
0 0 0 0
Handsearching naloxone 2015-2017, 
English
0 0 0 3
TOTAL N/A N/A 259 65 36 11
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 4 
Synthesis of Evidence
Common Themes:
• MAJOR:
– Academic Detailing
– Clinical Champion
– Current Research Rapidly Changing
• MINOR:
– EHR Alerts
– Accessibility of physical naloxone prescription
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 5 
Objectives:
• Providers/Participants will increase: 
– Knowledge base regarding naloxone
– Comfort level of naloxone co-prescribing
– Safer prescribing practices
• Expected Project Outcome:
– Increase in the rate of naloxone co-
prescriptions
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 6 
Background Information
• Opioids involved in 61% of all drug overdose 
deaths in 2014 (CDC, 2016c)
• Opioid overdoses have quadrupled since 1999 
(CDC, 2016c)
• Opioid prescriptions have also quadrupled during 
this time frame (CDC, 2016d)
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 7 
Background Information – Epidemic Proportions
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 8 
Since 2009, Drug overdose deaths have 
outpaced traffic accidents as the leading cause 
of injury death in the United States
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 9 
• State of Michigan
• Significant Increase between 2014-
2015 (13.3%)
• One of the highest OD death rates 
in the nation – 20.4 per 100,000 
(Ranked 15th highest)
• Leading Cause of injury death in 
Michigan 
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 10 
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 11 
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 12 
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 13 
Why NHBP?
• Health needs survey indicated:
– 11.9% of tribal members used RX drug for 
experience
– 3.97% admitted misuse of RX drugs in last 30 
days (Great Lakes Inter-Tribal Epidemiology Center, 2016)
• ACE Indicators
– 24.23% lived with a problem drinker or alcoholic 
before the participant turned 18
– 11.03% lived with someone who abused illegal 
street drugs or prescription drugs before the 
participant turned 18
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 14 
Early Opioid Prescribing Patterns Are Associated With Long 
Term Use 
• In a March 2017 Study, the Centers for Disease Control Found:
– Even One Prescription for an Opioid Can Be a Trigger For Opioid Abuse
– The Likelihood of Chronic Opioid Use Increases Most Sharply When:
• Patients Are Given a Long-Acting Pain Reliever
• Patients Are Given an initial 10 to 30 Day Supply of Opioids, 
• Patients Are Given More than 700 Morphine Milligrams Cumulative 
Dose, or
• A Second Prescription or Refill
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 16 
Why Naloxone Co-Prescribing?
• Named as a component in several opioid 
initiatives
– CDC (2016a) clinical guideline for safe opioid 
prescribing 
– USDHHS, 2016
• Effective
• Cost-Effective
• “Best-Practice”
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 17 
Cost & Benefit
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 18 
Naloxone Pharmacology
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 19 
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 20 
IHS Naloxone Co-prescribing
• Recently rotated to a new opioid
• Prescribed morphine equivalent daily (MED) dose of 50mg or more
• On long-acting opioids particularly if in conjunction with short-acting opioids
• Poly-opioid use
• Prescribed opioids greater than 30 days
• Over the age of 65 years
• Households with people at risk of overdose such as children or someone with a substance abuse 
disorder
• Patients who have difficulty accessing emergency medical services (distance, remoteness, lack of 
transportation, homelessness, and/or without phone services)
• Recent mandated substance use treatment, incarceration, or period of abstinence with history of drug 
abuse
• Concurrent prescription or over-the-counter medications 
• Benzodiazepines
• Antipsychotics
• Antiepileptics
• Muscle relaxers
• Hypnotics
• Antihistamines
• UNIVERSAL CO-PRESCRIBING????
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 21 
Arguments for Universal 
Co-Prescribing
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 22 
Opioid Safety Language
• Avoid word “overdose”
– Negative connotations 
– Prescription opioid users may not relate
• Instead use:
– “Accidental overdose”
– “Bad Reaction”
– “Opioid Safety”
– Use Epipen analogy
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 23 
Other Distribution Notes
• Nasal formulation
– Keep in pack
– Store between 59-77 degrees
– Protect from light
• May provide patient with “Quick Start 
Guide” (Included in NHBP policy)
• Opioid Safety pamphlet
• Have patient tell someone where the keep 
it!
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 24 
Documentation
• Able to pick from “Administered in 
Clinic”  (Thank you Kathie!)
• Document discussion in office note
• Follow NHBP policy
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 25 
Current NHBP Policy
• Copy included in packet
• Allows for “3rd Party Prescribing”
• Staff mandated to have annual training
• Naloxone stored in formulary (or will be)
• Adapt pharma training video
• Training completion form
• Log of distributed naloxone kits
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 26 
Adapt Pharma Video
• http://adaptpharma.com/news-
events/press-kit/
• Also accessible through “Narcan Now” app
• How would staff like this available for 
easier access?
– Email link?
– Install Shortcut to each computer?
– Have IT add link to intranet?
– Other ideas?
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
Slide 27 
Michigan Law Updates
• Signed into law on Wednesday, Dec. 28, 2016.  
• Public Act 383 of 2016.
• Authority
– This standing order is issued pursuant to Michigan law which 
allows the Chief Medical Executive (CME) to issue a standing 
order that does not identify particular patients at the time it is 
issued, for the purpose of a pharmacist dispensing the opioid 
antagonist naloxone. MCL 333.17701 et seq.,
• Authorization
– This standing order may be used by pharmacists to generate a 
prescription for Eligible Individuals to obtain naloxone from a 
pharmacy. This order is authorization for pharmacists to dispense 
naloxone and devices for its administration SOLELY in the FDA-
approved naloxone formulations and devices prescribed herein.
• Link to info regarding law: 
http://www.michigan.gov/documents/budget/Emergency_Rules_Opioi
d_Antagonists_572010_7.pdf
• http://www.legislature.mi.gov/(S(kxxcot1o5lsyf45ro11bge4c))/mileg.as
px?page=GetObject&objectname=2016-HB-5326
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Slide 28 
What Next?
• 12 week intervention
• Clinical Champion support
• MAPS reports for each provider
• Article in Fall Health Publication
• Other Resources in Packets
• Info posters in rooms
– Information for patients
– Visual Reminder for clinic staff
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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Questions??
 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
___________________________________ 
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